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Overall cancer survival rates steadily decline each year following diagnosis and side effects of 
chemotherapy restrict its use. The chemotherapeutic cis-diamminedichloro-platinum (cisplatin, 
CDDP) is poorly soluble and has dose limiting side effects. Nanoparticle delivery systems can 
deliver a higher dose of drug directly to the tumor by both active and passive targeting, holding 
promise of fewer side effects and greater anti-tumor efficacy. To date, few nanoparticle systems 
have been FDA approved for the treatment of cancer due to complicated physicochemical 
characterization, drug inactivation by the delivery system, scale-up challenges, and lack of 
demonstrated in vivo safety and efficacy.  Further research is needed in this area. 
This dissertation examined a naturally biocompatible carrier for delivery of CDDP: 
calcium phosphate (CaP). Three molecules were tested to stabilize CaP nanoparticles (nCaP) and 
increase injectability: sodium polyacrylate (D), sodium citrate (CIT) and carboxymethyl 
hyaluronic acid (CMHA). nCaP
D
CDDP and nCaP
CIT
CDDP were examined against a head & 
neck cancer (HNC) model, because HNC patients could greatly benefit from localized 
chemotherapy prior to surgical resection. Triple negative breast cancer (TNBC) with a 
CD44
high
/CD24
-/low
 cell phenotype has emerged as an important new target for 
chemotherapeutics.  CD44 is the major receptor for hyaluronic acid, targetable with CMHA. 
These studies showed all three molecules stabilized nCaP as measured by light scattering, zeta 
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potential, x-ray diffraction and transmission electron microscopy, and released biologically 
active CDDP as measured by in vitro release studies and in vitro cytotoxicity testing.  However, 
intratumoral (IT) delivery of nCaP
D
CDDP or nCaP
CIT
CDDP was not as effective as CDDP IT in 
vivo against murine and human HNC tumor models, due stabilizer inhibition of CDDP.  Surface 
plasmon resonance proved CMHA and nCaP
CMHACDDP bind CD44. CMHA didn’t inactivate 
CDDP and nCaP
CMHA
CDDP had comparable activity to free CDDP in vitro. Local delivery of 
nCaP
CMHA
CDDP did not demonstrate a benefit over local delivery of CDDP in a human TBNC 
mouse model, due to lack of even distribution of nanoparticles throughout the tumor where 
CDDP alone could freely diffuse. These studies show that localized delivery of CDDP remains a 
promising strategy to increase drug effectiveness while decreasing drug side-effects that 
negatively impact cancer patients. 
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Chapter 1 
Specific Aims and Background 
 
1.1 Specific Aims 
Despite a combination of surgery, radiation and/or chemotherapy overall survival rates for a 
majority of cancers steadily decline each year following diagnosis, with an estimated 1,600 
deaths per day in 2013
1,2
. Chemotherapy has many debilitating side effects because it kills 
normal replicating cells while killing cancer cells. Nanoparticles can deliver a higher dose of 
drug directly to the tumor by both active and passive targeting, with the goal of fewer side effects 
and greater anti-tumor efficacy
3–5
. However, few nanoparticle systems have been FDA approved 
for the treatment of cancer due to complicated physicochemical characterization, scale-up 
challenges
6
, and lack of demonstrated in vivo safety and efficacy
7
. Stabilizer molecules are often 
needed to prevent nanoparticle aggregation but may negatively interact with the drug
8–10
. 
Targeting ligands that may increase specific cancer cell interaction must be carefully attached to 
present the active groups to the cells
11–13
. In order to develop an efficacious nanoparticle delivery 
system, it’s important to have an understanding of how each component of the nanoparticle 
system interacts with the drug.  Although CDDP is an effective anti-cancer drug it has limited 
solubility and dose-limiting side effects including: nephrotoxicity, nausea, vomiting and anemia. 
Thus, there is a need to improve the delivery of CDDP.  
CaP offers a naturally biocompatible carrier for delivery of CDDP
14
. A stabilizer 
molecule is needed to prevent CaP nanoparticle aggregation and to increase injectability of the 
particulate delivery system
14,15
.  We have previously shown that CDDP released from sodium 
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polyacrylate (D) stabilized CaP nanoparticles (nCaP
D
CDDP) has comparable toxicity to free 
drug against cancer cells in vitro
16
. However, when attached to the nCaP
D
 the CDDP was 
significantly less toxic than free CDDP in vitro and our unpublished animal studies revealed a 
corresponding lack of in vivo anti-tumor efficacy relative to free drug. CDDP attached to CaP 
microparticles without stabilizer did not lose activity, but were not easily injectable, which led to 
the conclusion that further work was needed to identify an alternative stabilizer that would not 
inactivate the drug. The goal of these studies is to develop a stabilized, injectable calcium 
phosphate nanoparticle system for the delivery of CDDP that releases active drug and can 
furthermore be targeted to therapy resistant cancer cells. Therapy resistant cells have emerged as 
important target and in breast cancer those cells have a CD44
high
/CD24
-/low 
phenotype
17–19
. CD44 
is the receptor for hyaluronic acid, which is a widely used non-toxic biomaterial that could be 
used as a stabilizer of calcium phosphate when modified to contain carboxylate groups, such as 
carboxymethyl hyaluronic acid (CMHA)
20
. The envisioned biocompatible nanoparticle system 
may one day impact the longevity of cancer patients by enabling the sustained delivery of higher 
doses of CDDP directly to the tumor and the subset of therapy resistant cells through 
intratumoral injections with less toxicity.    
 
Aim #1: Select a stabilizer that achieves a highly drug loaded, stable nanoparticle delivery 
system. Hypothesis: If a molecule is a successful stabilizer for a calcium phosphate nanoparticle 
delivery system for CDDP then CDDP will bind to the stabilized nanoparticles and will be 
released slowly. In addition to the previously published stabilizing molecule sodium polyacrylate 
(Darvan ® 811, D); sodium citrate (CIT)
21
 and carboxymethyl hyaluronic acid (CMHA)
20
 were 
also tested. Particle size was assessed with dynamic light scattering (DLS), transmission electron 
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microscopy (TEM). X-ray diffraction (XRD) determined structure.  Inductively coupled plasma 
optical emission spectrometry (ICP-OES) determined Pt content which corresponds to CDDP. In 
vitro drug release was performed using a modified USP apparatus 4
22
.  
 
Aim #2: Examine the anti-cancer activity of CDDP loaded stabilized nanoparticles in vitro. 
Hypothesis: If the stabilized CaP nanoparticle delivery system does not inactivate CDDP, then 
the CDDP loaded nanoparticles will have equal or greater in vitro cytotoxicity than CDDP 
alone. Each stabilized nanoparticle delivery system (nCaP
x
CDDP, where x = D, CIT or CMHA) 
made in Aim#1 was analyzed to determine the drug concentration that inhibits proliferation by 
50% (IC50) using an MTS assay (Promega CellTiter Aqueous One). nCaP
x
CDDP and CDDP 
reacted with stabilizer was compared to CDDP alone to determine if the stabilizer affects the 
drug activity by itself or as part of the nanoparticle delivery system. Surface Plasmon resonance 
(SPR) examined the binding of nCaP
CMHA
CDDP and recombinant human CD44-Fc chimera 
antibody.  
 
Aim #3: Assess the in vivo anti-tumor effect of CDDP loaded nanoparticles after 
intratumoral delivery.  Hypothesis: If the nCaP
x
CDDP releases active CDDP at locally high 
concentrations in the tumor environment after intratumoral injections, then nCaP
x
CDDP treated 
mice should have reduced tumor growth rate without systemic toxicity as compared to free drug.  
Subcutaneous tumors from mouse and human cancer cells were initiated in the flanks of nude 
mice. Tumor volume and animal weight were measured daily after cell injections. Animals were 
treated with nCaP
x
CDDP intratumorally (IT) and, compared to a positive control of CDDP that 
can only be administered at a lower dose due to systemic toxicity and solubility limits. 
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1.2 Background 
In the United States, approximately 1.7 million new cases of cancer were diagnosed in 2013
2
.  
Cancer causes one in four disease related deaths in the United States, and an ever aging 
population is expected to drastically increase the number of cancer-associated deaths over the 
next 20 years.  The rate of cancer incidence has declined in the United States since 1975 yet it 
was estimated that over 1.6 million new people were diagnosed with cancer in 2013
2
. The 
National Institutes of Health estimate that the overall cost of cancer was approximately 201.5 
billion dollars, in 2008
23
.  This dissertation is focused specifically on treatments for head and 
neck cancer and breast cancer because of the large potential benefit to these patients from 
localized treatment prior to surgical resection.  Tumor reducing treatments could mean normal 
tissue is spared and chemotherapy side effects are reduced. The incidence, current treatments and 
outlook for each type of cancer is reviewed.  
1.2.1 Head and Neck Cancer  
Cancer of the head and neck is the 6
th
 most common cancer worldwide
24
.  In 2008, it was 
estimated that we spent 3.2 billion dollars on head and neck cancer (HNC) treatment in the 
United States
25
. It is commonly a squamous cell carcinoma found in the oral cavity, nasal cavity, 
nasal sinuses, oropharynx, hypopharynx, thyroid, lips, or larynx.  HNC is typically linked to 
damage from alcohol and/or carcinogens.  Recently, human papillomavirus (HPV) has also been 
elucidated as a driver for specific types of HNC.  It is estimated that 30% of HNCs, specifically 
those of the oral cavity/pharynx are associated with HPV with a specific genetic profile linked 
with HPV16-E6 oncogene expression
26–28
.  The complex anatomical locations of HNC are a 
major consideration during treatment planning for HNC patients.  Physicians are tasked with 
balancing the tumor control/survival and the patients’ quality of life and overall functionality, 
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during and following treatment.  There are often major complications with eating, breathing, 
speaking in addition to disfigurement associated with HNC.   
First line therapy is surgical resection but often surgery is very complicated or impossible 
because tumors are located close to vital anatomy, like the carotid artery
29
.  There has been some 
evidence that neoadjuvant therapy lowers the occurrence of distance metastases, but no benefit in 
loco-regional control or survival benefit was found
29
.  Radiotherapy and chemotherapy are the 
only options for unresectable tumors, which are often used in combination leading to significant 
acute and long term side-effects
30
.  CDDP is the standard chemotherapy for HNC patients which 
may be combined with other therapies, yet 50% of patients recur within 2 years following initial 
treatment
29
. This statistic highlights the necessity for advanced therapies to treat HNC.   
An injectable collagen gel carrying CDDP and epinephrine (IntraDose) was entered into 
several clinical trials for intratumoral therapy against a wide range of solid tumor based cancers.  
Separate clinical trials were conducted for the treatment of recurrent metastatic breast cancer and 
head and neck cancer, yet both trials failed due to lack of clinical and patient benefit combined 
with toxicity
31–35
.  There is currently no clinically approved molecular therapy for the treatment 
of HNC.  This is in part due to lack of molecular targets.  Generally, those that are currently in 
clinical trials are known drivers for carcinogenesis being applied to HNC, but are not truly 
specific to HNC.  The few molecular targets for HNC are epidermal growth factor receptor 
(EGFR), vascular endothelial growth factor and small molecules such as PI3 kinase and mTOR.  
Inhibitors or monoclonal antibodies have been developed to specifically target these drivers of 
cancer.  More than 35 clinical trials are being conducted specifically for HNC with targeted 
therapies alone or in combination with chemotherapy at varied disease stages
36,37
.  To date, none 
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of these approaches have stood out above current clinical practice for tumor shrinkage, mean 
survival time or disease free progression. 
 
1.2.2 Breast Cancer  
In the United States, 1 in 36 women will die from breast cancer
38
. The American Cancer Society 
estimates that 12% of women in the United States will have invasive breast cancer during their 
lives
2
.  Breast cancer risk increases with age and there are specific inheritable mutations that are 
strongly linked to susceptibility, in the BRCA1 and BRCA2 genes.  Treatment options are 
patient specific, but typically include surgical removal of the mass and often radiation therapy
39
. 
Many breast cancers over-express estrogen receptor (ER), progesterone receptor (PR) and/or 
human epidermal growth factor receptor 2 (HER-2).  Targeted hormone therapies are approved 
for patient specific treatment, based on their disease progression and hormone status.  It is 
estimated that 20-25% of women with invasive breast cancer will be classified as triple-negative, 
which means their tumor lacks expression of ER, PR, and HER-2
40
. Triple negative breast 
cancers (TNBC) are typically more aggressive and challenging to treat and cannot benefit from 
directed hormone therapy.  This sub-type of breast cancer will be focused on within this 
dissertation.  
Chemotherapy is the first line of defense for TNBC patients, instead of the molecular 
therapies directed against breast cancers
40
. If the cancer recurs, short-term and overall survival is 
significantly shorter for those patients than for non-TNBC patients
41
. Recurrence is hypothesized 
to be due to therapy resistant cells within the tumor
18,42
. Therapy resistant breast cancer cells 
have a common phenotype of CD44
+
/CD24
low 43–46
. Two studies examining patient samples 
histologically found a correlation between TNBC, CD44
+
/CD24
low
 and recurrence
17,19,47,48
.  In a 
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recent multi-center study, TNBC patients were treated with four cycles of CDDP (not commonly 
used to treat TNBC) and 50% of patients had a good response (22% complete pathologic 
responses)
49
.  This is an important finding for the work performed in Chapter 4 of this 
dissertation. 
In Dr. White’s laboratory, at the University of Connecticut Health Center (UCHC), 
human luminal A breast cancer cells, MCF-7s, were serially cultured into mammospheres for 5 
weeks, where each week cells were dissociated and placed into a new mammosphere culture.  
After 3 weeks, the cells had undergone epithelial to mesenchymal transition (EMT), such that 
when placed into two-dimensional culture they displayed a mesenchymal, CD44
+
/CD24
-/low
 
phenotype, referred to as luminal to mesenchymal switch (LMS) cells
50
.  This protocol was also 
performed with human luminal breast cancer cells, BT-474s.  BT-474 cells have a CD44
-
/low
/24
high 
phenotype
51,52
.  After serial mammosphere passages BT-474 cells underwent EMT, 
referred to as BT-474m cells, resulting in a mesenchymal phenotype including enhanced 
proliferation rate, up-regulation of vimentin, down-regulation of E-cadherin (unpublished data) 
and cell surface marker expression of CD44
+
/CD24
-
.  Importantly, these cells were negative for 
ER, PR and HER-2, making them a representative TNBC cell. This work was performed in Dr. 
Bruce White’s lab at UCHC and will be published elsewhere.  
1.2.3 Intratumoral Chemotherapy 
Most cancer treatments, especially chemotherapy, kill healthy cells as well as diseased cells, 
leading to debilitating systemic side effects. Physicians currently use systemic chemotherapy to 
treat most cancers despite the cancer being in a specific anatomical location
53
. CDDP for 
example is poorly soluble and causes nephrotoxicity, nausea, anemia and other deleterious side-
effects
54
. Intratumoral chemotherapy is the administration of chemotherapy directly into the 
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primary tumor, allowing for higher doses to be administered while systemic exposure is greatly 
reduced
55. Clinicians’ interest in intratumoral drug delivery systems began more than 60 years 
ago, yet advances in this technique have been insufficient to make intratumoral delivery a 
mainstream practice today
56
.  Early work delivering chemotherapy locally showed little benefit 
over systemic treatment, due to local toxicities and frequent complications
57–59
. The advent of a 
delivery system able to control the release of drug at a therapeutic concentration within a tumor 
would alleviate these problems and those due to systemic treatment.  
Several drug delivery systems aimed at intratumoral delivery of chemotherapeutic drugs, 
including CDDP, have been attempted with limited success
32,56,60–64
. IntraDose, a 
collagen/CDDP/epinephrine gel, had initial pre-clinical success, but ultimately failed to obtain 
approval for intratumoral treatment of head and neck squamous cell carcinoma from the U.S. 
Food and Drug Administration (FDA) due to toxicity and a lack of significant clinical benefit
31
. 
The collagen gel did not control the release of CDDP, leading to the addition of epinephrine (a 
vasoconstrictor) in an attempt to keep the CDDP within the tumor. The burst release of CDDP 
from the collagen gel ultimately was not controlled by the epinephrine
32–34
. Particulate 
bioceramics offer a non-inflammatory, biodegradable carrier for drug, non-viral gene, and 
protein delivery that may be able to overcome the problems of the previous work including 
uncontrolled drug release, side-effects due to the drug carrier and accumulation of drug in 
healthy tissues
65–67
. Calcium phosphate microspheres carrying an anti-angiogenic agent delivered 
locally to human uterine sarcoma xenografts caused a significant decrease in tumor weight 
compared to local treatment with the agent alone
68
. Calcium phosphate cements (CPCs) have 
been studied for local delivery of chemotherapy and concurrent bone healing. CDDP and 
caffeine delivered from calcium phosphate cement in a rat model of osteosarcoma significantly 
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reduced tumor size and mean survival of animals due to an extended release time of drug
69
. 
Delivery of cements and microparticles requires large gauge needles that are not attractive or 
common for delivery of drugs, therefore a readily injectable suspension would be more 
attractive. As with most local drug delivery vehicles, it is essential that the release of drug be 
controlled such release is stably within the therapeutic window to alleviate the necessity of 
several doses. If this is not achieved the delivery vehicle may not surpass the effectiveness of the 
drug alone.  
1.2.4 Nanoparticles for Cancer Therapy 
Attachment of drug to a particulate drug delivery system is a tactic that has long been employed 
to sustain drug delivery with promising results
70,71
.  Human capillaries are approximately 5 um in 
diameter, thus nanoparticles can freely travel throughout circulation
72
. Nanoparticles are 
attractive for the treatment of cancer for many reasons.  They can be designed to actively or 
passively target tumors.  Passive targeting by nanoparticles relies on the enhanced permeability 
and retention (EPR) effect, due to leaky tumor vasculature that allows particles to collect within 
the tumor.  Active targeting of nanoparticles involves the incorporation of a ligand, antibody or 
other specified moiety that will specifically bind cancer cell surface receptors with the goal of 
cell uptake.  Many chemotherapeutics are poorly soluble and have short biological half-lives.  
Nanoparticles can be loaded with high concentrations of chemotherapeutic drug increasing their 
solubility and often the drugs’ residence time in the body.  In recognition of the vast 
opportunities nanoparticles offer for advances in cancer diagnosis and treatment, the National 
Cancer Institute (NCI) created the Nanotechnology Characterization Laboratory (NCI-NCL).  
Researchers can submit applications to NCI-NCL for pre-clinical characterization and toxicity 
testing of their nanoparticles.  To date, FDA approved nanoparticle therapies for the treatment of 
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cancer is limited, due in part to the complexity of each systems’ components and their relative 
biological effects
6
.  
Nanoparticles can be synthesized from a wide range of materials including: metals, 
natural or synthetic polymers, ceramics or proteins.  Liposomes were one of the first drug 
delivery technologies developed. Doxil
®
 (Janssen Products, LLC) is an example of an FDA 
approved PEGylated-liposomal formulation of doxorubicin.  Doxil
®
 is indicated for the treatment 
of recurrent ovarian cancer and relapsed or refractory multiple myeloma
73
.  Polyethylene glycol 
(PEG) coating of nanoparticles (PEGylation) limits their detection by the immune system, 
termed stealth nanoparticles
74
.  Albumin nanoparticles carrying paclitaxel, Abraxane
® 
(Celgene 
Corporation), is indicated for the treatment of metastatic breast cancer, advanced non-small cell 
lung cancer and recently for metastatic pancreatic adenocarcinoma
75
.  
There has been some success in liposome-based drug delivery systems for cancer therapy 
but further effort is necessary to make them inert and long-circulating in blood, able to efficiently 
bind and transfer with  targeted sites, and able to sustain release of active components after 
targeting
5,13,74,76,77
. Clinical trials have been conducted with a liposomal PEGylated CDDP 
delivery system, SPI-77, for the treatment of non-small cell lung cancer as well as recurrent 
epithelial ovarian cancer. In both studies patients failed to significantly benefit from the 
treatment overall in addition to significant concerns regarding high lipid load combined with 
large deposits of platinum in non-diseases tissues throughout the body
78,79
.  Biodegradable 
polymer-based drug delivery systems often have acidic byproducts, which can produce adverse 
effects on the body or the drug attached or encapsulated
4,60,71,80
. Naturally occurring biopolymers 
or synthetic biopolymers such as polypeptides can also be employed as drug carriers, but their 
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quality, reliability and the high cost of preparation can often prevent their usage
81
.  These 
limitations provide the motivation for continued research in biomaterials for drug delivery.  
1.2.5 Polymeric Stabilization of Nanoparticles 
Stability is a major concern for nanoparticle formulations.  If nanoparticles agglomerate in 
suspension, they are no longer nanometer in size and will fall out.  The most common approach 
to enhancing nanoparticle stabilization is with the addition of polymers and/or surfactants to the 
surface of the nanoparticle.  PEG is likely the most common polymeric solution to nanoparticle 
instability, by steric stabilization with the brush-like corona it creates around particles.  
PEGylation is often performed on liposomal formulations where it serves not only as a colloidal 
stabilizer but also as a biological stabilizer, allowing the liposomes to avoid opsonization by 
serum proteins
74,82
.  Doxil
® 
is an example of an FDA approved PEGylated liposomal 
formulation.  Calcium phosphate nanoparticles carrying genetic material have also been 
PEGylated for pH sensitive intracellular delivery of payload
10,83
.  Natural polymers such as 
chitosan have been utilized to stabilize nanoparticles.  Calcium phosphate has been effectively 
stabilized by chitosan for gene transfection and drug delivery
84,85
.  Additional methods to 
stabilize calcium phosphate nanoparticles will be discussed thoroughly in the next section.  
1.2.6 Calcium Phosphate Nanoparticles  
Significant research has been conducted for the use of CaP as a bone replacement in the form of 
cement or particles
69,86–88
.  Due to its inherent biocompatibility, CaP has been elucidated as an 
attractive biomaterial for a wide range of applications, such as a vector for gene delivery, probe 
diagnostic imaging, or adjuvant for vaccinations
84,89–92
.  They have a high affinity to proteins, 
DNA, enzymes and cells giving them great potential as effective delivery vehicles
65,83,89,93
. The 
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reactive crystal surface of calcium phosphate particles facilitates rapid binding of charged and 
even neutral molecules to its surface and control of molecule release
67,94
. Nanoparticle 
formulations of calcium phosphate have been shown to effectively transport several types of 
molecules across cell membranes
94–96
.  
 Particulate CaP can be synthesized via wet precipitation. Original interests in the 
controlled synthesis of CaP were to understand and recapitulate the formation of bone and teeth 
in vertebrates
97
.  CaP nanocrystals can be synthesized without stabilizer, but careful control of 
the precipitation and immediate freeze drying is essential to avoid conversion and 
agglomeration
66
.  These nanocrystals are often sintered or otherwise fused together to create 
large biomaterial scaffolds, for bone or tooth applications.  For drug delivery, Barroug et al. 
showed poorly crystalline and amorphous calcium phosphate are more reactive than crystalline 
particles due to more surface defects allowing for greater drug adsorption
15
.  
 Many approaches have been applied to the synthesis of stabilized CaP nanoparticles 
(nCaP).  Stabilization has been achieved by incorporating DNA into the precipitated nCaP, 
which could then be coated with polymers for enhanced transfection efficiency
89,93,95,98
.  nCaP 
can be stabilized by the addition of sodium citrate due to the interactions of the carboxylate 
groups of the citrate and the Ca
21,99
.  A range of polymers have also been utilized to stabilize 
nCaP during precipitation including: sodium polyacrylate
16
, PEG-block-poly(aspartic acid)
10
, 
polyethyleneimine
100
, and carboxymethyl cellulose
94,101
. Specific applications of calcium 
phosphate for delivery of chemotherapeutics have been somewhat limited in comparison to 
liposomal and polymeric formulations.  Recently, Iafisco et al. reported targeted cellular uptake 
of biomimetic apatite nanocrystals carrying doxorubicin, but their in vitro cytotoxicity was not 
greater than free doxorubicin
102
.  The same group has shown that biomimetic hydroxyapatite 
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nanoparticles can bind and release cationic, anionic and neutral drugs for anti-cancer and 
simultaneous bone regeneration applications
103
. Work in our lab using sodium polyacrylate to 
stabilize nCaP for the delivery of CDDP for localized treatment of head and neck cancer will be 
further explored in the following chapter.  CDDP is bound to nCaP utilizing a cationic, aquated 
species of CDDP. The free Cl ions in physiological environments is a driving force for CDDP 
release (Figure 1.1 A)
14,15
. Additionally, CaP is known to dissolve in acidic pH, similar to that 
found in the tumor microenvironment and lysosomes within cells (Figure 1.1 B)
104–107
.  
1.2.7 Summary 
Treatments for cancer patients can be limited due to anatomical location.  Surgical resections for 
HNC can be disfiguring and dangerous, and localized radiation causes major side-effects 
drastically lowering quality of life for patients
30
.  CDDP is an effective chemotherapeutic, but is 
limited due to low solubility and nephrotoxicity.  Localized delivery of a high dose of CDDP to 
shrink the tumor and minimize side-effects could greatly benefit patients.  TNBC patients have 
limited treatment options, because their cancer presents with none of the commonly targeted 
hormone receptors in standard BC hormone treatments.  Localized treatment with a nanoparticle 
targeted to CD44
+
/CD24
-/low
, therapy resistant breast cancer cells is an attractive approach to 
prevent difficult to treat recurrence.  Calcium phosphate nanoparticles are biocompatible and 
known to bind and release CDDP effectively, but require effective stabilization. Thus this 
dissertation evaluates stabilizer candidates for: (1) ability to stabilize nCaP, (2) allow for 
biologically active CDDP to release from the nanoparticles, and (3) effectively deliver a local, 
high dose of CDDP to tumors in vivo to delay tumor growth while causing fewer side-effects 
than systemic CDDP. We demonstrate that localized delivery of chemotherapy remains a 
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promising strategy to increase drug effectiveness while decreasing drug side-effects that 
negatively impact cancer survivors. 
 
 
Figure 1.1: Schematic showing the release mechanism for the nCaPxCDDP delivery system.  (A) 
The presence of Cl-
 
ions is a driving force for CDDP release from nCaP, resulting in re-formation 
of native CDDP from the bound aquated form of CDDP (B) In acidic pH, like that within tumors 
or in the lysosome, nCaP will dissolve, releasing active CDDP. 
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Chapter 2 
Sodium Polyacrylate Stabilized Calcium Phosphate Nanoparticles for Delivery of 
Cisplatin 
2.1 Introduction 
Calcium phosphate nanoparticles (nCaP) are an attractive vehicle for the delivery of therapeutics 
due to their biocompatibility, low cost, and ease of manufacture
15,89,91,108,109
.  Previous work in 
our lab showed that sodium polyacrylate (Darvan® 811, D) could effectively stabilize nCaP 
(nCaP
D
)
 
, and allow binding cisplatin (CDDP), a commonly used clinical chemotherapeutic to 
form a drug delivery system for CDDP, nCaP
D
CDDP
16
.  The stabilization of nCaP is achieved 
by interaction of the free carboxylate groups in each monomer unit of D with the calcium rich 
surface of calcium phosphate. The research described in this chapter builds upon that promising 
in vitro data published by Cheng & Kuhn, 2007
16
. Working towards a successful clinical drug 
delivery nanoparticle system, it is essential that parameters of synthesis be controlled and the 
resulting product be essentially the same from batch to batch
6
. In addition to batch to batch 
consistency, product stability is essential to define.  Essential characteristics of nCaP
D
CDDP 
include particle size, drug loading, and cytotoxicity.  We therefore examined these parameters in 
studies of repeatability & stability, prior to conducting efficacy studies of nCaP
D
CDDP. 
CaP precipitated without stabilizer has been shown to effectively delivery CDDP, but is 
not readily injectable.  Here we made a similar non-stabilized CaP, microCaPCDDP, to examine 
as a positive control.  Both nCaP
D
CDDP and microCaPCDDP were tested against three different 
cell lines: SCCVII, FaDu and A2780cis. The latter two cell types are examples of CDDP 
resistant human cell lines, HNC and ovarian cancer, respectively.  It was hypothesized that the 
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nanoparticle formulation could overcome CDDP resistance via direct nanoparticle uptake.  Yang 
et al. recently published CDDP core micelles with a PEGylated corona that could overcome 
CDDP resistance via enhanced cellular uptake, followed by drug release intracellularly
110
. The 
overall goal for this chapter was to establish a preclinical data set for the treatment of head and 
neck cancer (HNC) with nCaP
D
CDDP administered intratumorally (IT) to suppress tumor 
growth and decrease toxicity associated with CDDP administered systemically.  Efficacy against 
a mouse HNC cell line was examined in vivo and compared to CDDP administered systemically 
(intraperitoneal, IP) or locally (intratumoral, IT). 
2.2 Materials and Methods 
2.2.1 Materials 
Ca(NO3)2·4H2O (Sigma C1396), K2HPO4 (Sigma S1804), , Pt(NH3)Cl2 (CDDP, Sigma P4394), 
and AgNO3 (Silver Nitrate, Sigma S6506) used to prepare the nanoparticles were all purchased 
from Sigma-Aldrich, (St. Louis, MO).  Sodium polyacrylate, Darvan® 811 (D), was supplied by 
R.T. Vanderbilt (Norwalk, CT). CDDP was prepared at 1 mg/mL in sterile saline (0.9% NaCl), 
unless otherwise noted. The molecular structure of D is shown in Figure 2.1.  
Murine squamous cell carcinoma of the head and neck, SCCVII cells were kindly 
provided by Dr. C. Johnson at the Roswell Park Cancer Institute.  Cells were maintained in 
RPMI 1640 (Gibco 11875), containing 12% heat-inactivated FBS and 1% penicillin 
streptomycin.  FaDu cells from ATCC and human CDDP resistant ovarian cancer A2780cis cells 
were used for intro cytotoxicity evaluation of the nanoparticles. FaDu cells were maintained in 
MEM (Gibco 10370) containing 10% heat-inactivated FBS, 1 mM sodium pyruvate (Invitrogen 
11360), 2 mM L-glutamine (Invitrogen 25030), 1% penicillin streptomycin. A2780cis cells were 
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maintained in RPMI 1640 (Gibco 21870) with 10% FBS and 2 mM L-glutamine where every 
third passage contained 1 µM CDDP to maintain CDDP resistance. 
C3H/HeJ mice were purchased from Jackson Laboratory, (Bar Harbor, ME) and used for 
studies at 6-8 weeks of age. 
2.2.2 nCaP
D
CDDP Production and Optimization 
Figure 2.2 is a graphic representation of the nCaP
D
 production procedure. nCaP
D
 was made via 
precipitation of equimolar and equal volume solutions of Ca(NO3)2 and K2HPO4, where the 
phosphate solution was manually poured into a stirred calcium solution, followed by the addition 
of 1.67(v/v)% Darvan®811 (sodium polyacrylate). During studies to optimize the nCaP
D
CDDP 
formulation, batches were made using half the concentration of D that is in the standard 
formulation, these particles are referred to as: nCaP
D/2
CDDP. Additionally, batches were 
synthesized that contained no stabilizer, creating CaP microcrystals (microCaP). For 
nCaP
D/2
CDDP and microCaP all procedure steps following precipitation remained the same as 
normal nCaP
D
CDDP preparation. Mixing was allowed to continue for one hour.  nCaP
D
 was 
collected via centrifugation, washed with ultrapure H2O then centrifuged again. Aquated CDDP 
(Aq CDDP) was made as previously reported
16
. Briefly, 90 mM AgNO3 was reacted with a 1 
mg/mL CDDP solution prepped in Ultrapure water at a 2:1 molar ratio. The reaction was allowed 
to occur for at least 24 hours, after which precipitate was removed with three centrifugation steps 
followed by 0.2 µM filtration. Binding solution was prepared as a 1:1 solution of 1:1 Aq CDDP 
at 1 mg/mL to 20 mM potassium phosphate buffer (KPB) pH 6.8. Binding of the Aq CDDP to 
nCaP
D
 was allowed to occur for ~24 hrs. at 37°C at a concentration of 4 mg nCaP
D
 per 1 mL 
binding solution. Binding solution was removed via centrifugation and a wash step with 10 mM 
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KPB, followed by a final centrifugation to concentrate the nCaP
D
CDDP.  nCaP
D
CDDP was 
diluted with ultrapure H2O to form a suspension injectable through a 25G needle. CDDP content 
was determined by inductively coupled plasma-optical emission spectroscopy (Perkin Elmer® 
Optima™ 5300 DV, ESIS Inc., Cromwell, CT).  
2.2.3 nCaP
D
CDDP Physical Characterization 
Transmission electron microscope (TEM) images were taken using a Hitachi H-7650 TEM 
(Hitachi High-Technologies Canada, Inc., Toronto). TEM samples were prepared by sonicating 
the particle suspension and diluting the suspension 26x in 10 mM citrate solution then 10x in 
70% ethanol. A 5 uL sample was placed on a formvar carbon coated 300 mesh Cu grid. Sample 
sat for 1min and then any excess solution was removed using filter paper. Prior to imaging the 
sample completely dried in air for 5 min.  Samples were imaged at 80 kV with the TEM.  X-Ray 
diffraction (XRD) was performed on lyophilized nCaP
D
 using a Bruker AXS D2 Phaser (Cu 
radiation, λ =1.54184 Å) (Bruker Corp., Germany).  Particle size analysis was performed using a 
90 Plus Particle Sizer (Brookhaven Instruments, NY). Drug loading (ug CDDP/mg nCaP
D
) was 
determined by Pt analysis of the suspension for ug CDDP and drying 3 replicates of 100 uL 
nCaP
D
 CDDP suspension for ~24 hrs at 37°C to determine the mg nCaP
D
 in 100 uL suspension.  
2.2.4 nCaP
D
CDDP In Vitro Drug Release Studies 
Two in vitro drug release studies were performed. One was performed using a ready to use 
dialysis device, (Float-A-Lyzer® G2, Spectrum Laboratories Inc., Rancho Dominguez, CA), 
with a molecular weight cut off of 100 kD.  0.55 mL of nCaP
D
CDDP suspension (CDDP 
concentration of 4 mg/mL) was loaded in to the dialysis device and placed in 22 mL of 10 mM 
PBS.  The pH of the PBS was adjusted to 6.8 to mimic an acidic tumor microenvironment. 
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Beakers were capped, placed on an orbital shaker, and incubated at 37°C.  Release samples were 
drawn at 1h, 6h, 1d, 3d, 5d, 7d, and 14d.  At each time point 5 mL of release solution was taken 
and replaced with 5 mL of fresh PBS. The second release study used a modified USP apparatus 4 
with a dialysis sac
22
.  0.4 mL of nCaP
D/2
CDDP suspension (CDDP concentration 5 mg/mL) was 
placed into the dialysis sac and 40 mL of 50 mM PBS, pH 6.8 was used for release media.  
Samples were removed in 4 mL volumes at 4, 6, 12 hr, 1, 3, 5, 7 and 9 days. CDDP content in 
the release solution was determined by inductively coupled plasma-optical emission 
spectroscopy (Perkin Elmer® Optima™ 5300 DV, ESIS Inc., Cromwell, CT).   
2.2.5 Cytotoxicity  
Cytotoxicity experiments were conducted using SCCVII cells plated in 96 well plates at 20,000 
cells/mL with 50 uL suspension per well. Cells were allowed to proliferate for 24 hours 
following which drug was added in 50 uL volumes. The following groups were examined: 
CDDP in saline, Aq CDDP, D alone, nCaP
D
, nCaP
D
CDDP and released drug from nCaP
D
CDDP 
at 3 days (nCaP
D
CDDP (R)). Each group was serially diluted 1:3 across the plate using PBS. 
Cells were assayed 48 h after adding drug using in an MTS assay (CellTiter 96® AQueous One, 
G3580, Promega Corp., Madison, WI), where metabolic activity was determined using a 
Spectramax Plus
384 
Spectrophotometer (Molecular Biosciences, Sunnyvale, CA) at an 
absorbance of 490nm. Background correction was performed for any CaP treated groups due to 
background interference.  Background plates were handled in the same manner as test plates, but 
no CellTiter reagent is added prior to reading the absorbance.  To determine the IC50 (50% 
inhibitory concentration) a non-linear regression curve fit analysis was performed with at least 
four replicates per group.  All cytotoxicity experiments were repeated at least twice.  Statistical 
significance was determined. 
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To compare the cytotoxicity of CDDP, nCaP
D
CDDP, and microCaPCDDP three 
difference cell lines were examined: SCCVII, FaDu and A2780cis. The latter two cell types are 
examples of CDDP resistant human cell lines.   
2.2.6 Process Repeatability, Product Stability and Stabilizer Optimization 
To assess the repeatability of the production of nCaP
D
CDDP three separate batches were made 
within one week’s time following the procedure as described in section 2.2, using the same batch 
of Aq CDDP, all other components were prepared fresh. To assess stability, nCaP
D
CDDP made 
two (5-11-09) and three years (9-8-08) prior was compared to a batch of nCaP
D
CDDP made 
freshly.  In an approach to reduce the amount of D added to create particles, batches were made 
using 0.835% (v/v)% D to produce nCaP
D/2
CDDP which was compared to a standard batch of 
nCaP
D
CDDP.  For each of these measures drug loading, particle size and IC50 value against 
SCCVII cells were examined.  
Findings from the initial repeatability study, led to modification to the synthesis and Aq 
CDDP binding procedure. The graphic representation of the changes to the synthesis procedure 
is in Figure 2.3.  Three batches of nCaP
D 
were pooled prior to rinsing with H2O. After 
centrifugation, the particles were resuspended in binding solution and split into three tubes for 
overnight binding. All remaining steps were performed as described previously.  
2.2.7 nCaP
D
CDDP In Vivo Maximum Tolerable Dose Study 
An initial maximum tolerable dose (MTD) study was performed in 10-12 week old C3H/HeJ 
female mice. Tumors were initiated intradermally using 7 x 10
4 
SCCVII cells in 20 uL at a 
concentration of 3.5 x 10
6 
cells/mL. The MTD was defined for the purposes of this study as the 
maximum dose that could be administered to a mouse that will result in less than 15% weight 
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loss.  Each mouse received one, intratumoral (IT) injection of the nanoparticle suspension via a 
25-gauge needle; (2-6 mice/group) where groups included: 10, 14, 18, and 23 mg/kg 
nCaP
D
CDDP.  Mouse weight was monitored daily for twelve days, (by day 8 all mice had 
recovered from the normal initial weight loss seen with CDDP doses in the first few days, or had 
exceeded 15% weight loss).  Mice exceeding 15% weight loss were euthanized. 
A second MTD study was conducted in 12 week old female CH3/HeJ mice without 
tumors. All doses were administered once, subcutaneously. Three animals were in each group. 
Groups were as follows: 9 mg/kg CDDP, 9, 18, 23 and 27 mg/kg nCaP
D
CDDP.   
2.2.8 nCaP
D
CDDP in vivo anti-tumor efficacy and toxicity studies 
C3H/HeJ mice were inoculated with 5x10
5
 SCCVII cells in 20 uL of 2.5x10
6
 cells/mL PBS 
intradermally in the right rear flank via a 25-gauge needle.  A total of 42 female, 8 week old, 
C3H/HeJ mice were included in the study, (6 mice/group, 7 groups). Tumors were measured 
daily using digital calipers to calculate the tumor volume as follows:  V = W
2
 * L * 0.4, where W 
= width, L = length, and V = volume.  
When tumor volume reached 100 ± 20 mm
3 
animals were enrolled into treatment groups 
as follows: 20 µL of saline (IT), 10 µL of nCaP
D
 (IT), 6.5 mg/kg CDDP (IT), 6.5 mg/kg CDDP 
(IP), 6.5 mg/kg nCaP
D
CDDP (IT), or 12 mg/kg nCaP
D
CDDP (IT).  Systemic toxicity was 
evaluated by weight change and overall grooming/appearance.  Tumor volume and mouse 
weight were monitored daily. Mice were euthanized due to significant weight loss (> 15%), a 
tumor length measurement greater than 20 mm, or completion of the study (day 30).   
The efficacy study was repeated with modifications due to fast growing necrotic tumors 
in the first study. 12 week old C3H/HeJ mice were injected subcutaneously with 4x10
4 
SCCVII 
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cells in 50 uL of a 80% BD Matrigel (Franklin Lakes, NJ) and 20% cells + base media. 32 mice 
were entered into treatment groups when their tumor volume reached 160 ± 10 mm
3
 with 6 
mice/group. The groups were as follows: 50 uL Saline (IT), 10 mg/kg CDDP (IP), 2.2 mg/kg (50 
uL) CDDP (IT) and 11 mg/kg nCaP
D
CDDP (IT).  The volume of 50 uL was an estimate based 
on clinician collaborator suggestion to administer only what would be feasible to administer to a 
solid human tumor. This is considered to be 20% of the total tumor volume
111,112
.  Here that 
would have been a volume of 30 uL, but the dose of CDDP that could be administered in a 30 uL 
volume was very low. We therefore used 50 uL which is approximately 31% of the tumor 
volume at time of treatment.  All animal experimental procedures were approved by the Animal 
Care and Use Committee of the University of Connecticut Health Center, (Farmington, CT). 
2.2.9 In Vitro Cytotoxicity Assessment of Darvan, due to Toxicity Shown In Vivo 
Due to unforeseen weight loss to animals administered 11 mg/kg nCaP
D
CDDP (IT) compared to 
10 mg/kg CDDP IP, in vitro cytotoxicity testing was employed. We examined the toxicity of D 
alone against SCCVII cells. The D was prepared at a concentration of 65 mg/mL. This 
concentration was picked based on thermogravimetric analysis of nCaP
D, 
which revealed nCaP
D 
is approximately 27% D by weight.  We then based our calculations on the average mg nCaP
D 
in 
the top concentration of nCaP
D
CDDP: used in the top concentration of cytotoxicity tests relative 
to CDDP.  Additionally, SCCVII (murine HNC), FaDu (human CDDP resistant HNC) and 
A2780cis (human ovarian CDDP resistant cancer) cells were used to examine the cytotoxicity of 
nCaP
D
CDDP compared to CDDP, Aq CDDP and microCaPCDDP.  
2.2.10 Statistical Analysis  
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Statistical analysis was performed using an unpaired t-test for comparison of two batches. When 
comparing three or more batches a one-way ANOVA was used with either a Tukey (when 
comparing all groups to one another) or Dunnet (when comparing test groups to a control group) 
post-test. A P-value of less than 0.05 was considered statistically significant.  Data is presented 
as a mean value with its standard deviation indicated (mean + SD).   
2.3 Results 
2.3.1 Physical Characterization of nCaP
D
CDDP 
Transmission electron microscopy (TEM) (Figure. 2.4 A and B) and particle size analysis via 
dynamic light scattering showed that nCaP
D
CDDP in suspension form small aggregates with an 
average size of 150 ± 40 nm.  Average drug loading of the suspension is 75 + 10 µg CDDP/mg 
nCaP
D
.  XRD of lyophilized nCaP
D 
shows a
 
poorly crystalline hydroxyapatite (HA), Figure 
2.5
113
. 
2.3.2 nCaP
D
CDDP In Vitro Release Studies  
The release profile of the nCaP
D
CDDP using a Float-a-Lyzer® device in PBS, pH 6.8, at 37° C 
can be seen in Figure 2.6 A. In comparison, in vitro release of CDDP from nCaP
D/2
CDDP was 
performed using a United States Pharmacopeia (USP) apparatus 4 modified with a dialysis 
adapter (Figure 2.6 B).  nCaP
D
CDDP and nCaP
D/2
CDDP show continuous in vitro release. 
nCaP
D
CDDP released 47% of the total CDDP bound after 12 days in the Float-A-Lyzer® 
system. A burst release was exhibited in the first 3 days, with slower, continuous release out to 
day 12.  After 9 days in the modified USP apparatus 4 nCaP
D/2
CDDP released 76% of the total 
CDDP bound. Again there was a burst release over the first 3 days, followed by a tapering of 
release over the remainder of the experiment.  
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2.3.3 Cytotoxicity  
Figure 2.7 A, shows a non-linear regression curve fit analysis for a CDDP cytotoxicity 
experiment, with four replicates. Figure 2.7 B shows an example of background correction when 
examining nCaP
D
CDDP. The blue line represents the original data measured from the test plate 
including cells, nCaP
D
CDDP treatment and CellTiter 96® AQueous One reagent after 4 hours of 
incubation. The green line is the background plate that includes cells and nCaP
D
CDDP treatment. 
These absorbance values were then subtracted from the original data to result in the pink line 
which represents the corrected data. The corrected curve is what is used to calculate the IC50.  
The carrier alone, nCaP
D
, did not show any significant toxicity at a concentration of 20 ug/mL 
that matches its average concentration in nCaP
D
CDDP at the IC50 relative to CDDP (Figure 
2.8). 
The in vitro cytotoxicity of nCaP
D
CDDP and the released CDDP from nCaP
D
CDDP 
(nCaP
D
CDDP) were compared to CDDP and Aq CDDP against SCCVII cells using an MTS 
assay. The respective curves are plotted in Figure 2.9 A and the calculated IC50 values are 
plotted in Figure 2.9 B. CDDP released from nCaP
D
CDDP has the same cytotoxicity as CDDP 
alone and Aq-CDDP.  nCaP
D
CDDP was significantly less cytotoxic than CDDP (P < 0.0001). 
2.3.3 Process Repeatability, Product Stability and Stabilizer Optimization 
The relative stability of batches of nCaP
D
CDDP was examined. The particle size of batches 
stored for 2 or 3 years was significantly larger (152 & 158 nm, respectively) than that made 
freshly (125 nm)(P < 0.0001) (Figure 2.10 A).  The drug loading also varied with one batch 
having significantly lower drug loading (63 ug CDDP/ mg nCaP
D
) than the freshly made control 
(87 ug CDDP/ mg nCaP
D
) (P < 0.05) (Figure 2.10 B). Lastly, the IC50 value of the batch stored 
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for 3 years (3.3 ug/mL) was significantly higher than the fresh batch (2.8 ug/mL) (P < 0.0001) 
(Figure 2.10 C). 
nCaP
D/2
CDDP synthesized using half the concentration of D compared to nCaP
D
CDDP 
created significantly smaller nanoparticles, 120 nm vs 125 nm (P = 0.0213) (Figure 2.11 A), with 
a significantly higher drug loading 105 vs 87 ug CDDP/ mg nCaP
D
 (P = 0.0056) (Figure 2.11 B).  
There was no statistical difference between the IC50 values against SCCVII cells 2.8 vs 3 ug/mL 
for D/2 (Figure 2.11 C). 
The batch to batch repeatability was examined by comparing three separately synthesized 
batches using particle size, drug loading, yield and IC50 values against SCCVII cells. Batches 
were labeled: nCaP
D
CDDP 1, nCaP
D
CDDP 2 and nCaP
D
CDDP 3 and all results are listed in this 
order. The yield varied from batch to batch, 0.8, 0.9, vs 1.2 g (Figure 2.12 D and E), no statistics 
could be performed. Interestingly, the yield did not follow the same trend after Aq CDDP 
binding: 1.1, 1.5, vs 1.4 g.  No significant differences were found between the three batches in 
particle size 168, 202, vs 161 (Figure 2.12 A). The drug loading varied significantly from batch 
to batch 66, 124, vs 81 ug CDDP/ mg nCaP
D
 (P < 0.0001) (Figure 2.12 B). The IC50 of batch 2 
at 1.5 ug/mL significantly varied from  batches 1 and 3, at 1.2 ug/mL (P < 0.001) (Figure 2.12 
C). 
To address issues with batch to batch repeatability, modifications were made to the 
nanoparticle synthesis procedure at shown in Figure 2.3, resulting batches are labeled 
nCaP
D
CDDP A, nCaP
D
CDDP B and nCaP
D
CDDP C.  These modifications led to a more 
uniform nCaP
D 
and nCaP
D
CDDP.  Although the particle size of batch C was significantly 
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smaller than A and B (P = 0.0077) (Figure 2.13 A), the drug loading of all three batches was 
uniform. Their resulting IC50 values against SCCVII cells were also uniform (Figure 2.13 C). 
2.3.4 nCaP
D
CDDP In Vivo Maximum Tolerable Dose Study 
A maximum tolerable dose (MTD) study was performed in C3H/HeJ mice with tumors.  The 
MTD is defined as the maximum dose that can be administered to a mouse that will result in less 
than 15% weight loss and is a measure of systemic toxicity of the tested materials. The dose of 
14 mg/kg nCaP
D
CDDP IP is the maximum tolerable dose that can be administered to a C3H/HeJ 
mouse without experiencing significant weight loss (> 15%).  The average weight loss following 
a single treatment of 10, 14, 18 and 23 mg/kg nCaP
D
CDDP IT dose are shown in Figure 2.14 A-
D, respectively. The 18 and 23 mg/kg dose groups each had one mouse whose weight loss 
dipped below the acceptable 15%, therefore these doses are not tolerable. 
A second MTD study was performed in CH3/HeJ mice this time without tumors. Animals 
were administered treatment subcutaneously, once with three animals per group. In this study 9 
mg/kg CDDP (Figure 2.15 E) was compared 9, 18, 23 and 27 mg/kg nCaP
D
CDDP (Figure 2.15 
A-D). Both of the 9 mg/kg treatments were well tolerated. One of the mice receiving CDDP 
experienced10% weight loss, but was able to recover. The animals treated with 9 mg/kg 
nCaP
D
CDDP lost a maximum of 5% of the weight at the time of treatment. One of the animals in 
the 18 mg/kg group lost more than 15% of her weight and therefore that dose and the higher 
doses of 23 and 27 mg/kg were not well tolerated. These higher doses were therefore not 
considered for animal efficacy studies. A dose of 12 mg/kg was chosen for the first efficacy 
study.   
2.3.5 nCaP
D
CDDP In Vivo Anti-Tumor Efficacy and Toxicity Studies 
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The in vivo anti-tumor efficacy of the nCaP
D
CDDP was evaluated using SCCVII tumors in 
CH3/HeJ mice.  When tumors reached 100 ± 20 mm
3  
animals were enrolled into a treatment 
group (6 mice/ group) Tumors were treated once with either CDDP intraperitoneally (IP) at 6.5 
mg/kg or intratumorally (IT) with  saline (20 uL), CDDP (6.5 mg/kg), nCaP
D 
(10 uL) or 
nCaP
D
CDDP (6.5 or 12 mg/kg).  The change in tumor volume and mouse weight was evaluated 
for 20 days post treatment, (Figure 2.16 A - F). 6.5 mg/kg CDDP IT resulted in delayed tumor 
growth with one tumor completely going away and two not growing beyond their volume at 
treatment (Figure 2.16 D). The IT dose of CDDP was significantly more effective at delaying 
tumor growth than the same dose delivered IP (Figure 2.17).  As expected, saline IT and nCaP
D
 
IT (no CDDP) had no effect preventing tumor growth.  A one-way ANOVA was performed 
comparing average tumor volume per group for each day. On day 6 following treatment 12 
mg/kg nCaP
D
CDDP, 6.5 mg/kg CDDP IP & IT were significantly more effective at delaying 
tumor growth than the vehicle control (saline) (P < 0.05) (Figure 2.18 A). Additionally, at day 6 
it was determined that 6.5 mg/kg CDDP IT was significantly more effective than the same dose 
of nCaP
D
CDDP IT (P < 0.05). No animals in this study lost more than 10% of their weight at 
treatment.  Maximum weight loss was compared across groups, relative to their respective 
maximum weight loss day post-treatment (Figure 2.18 A).  Here it was found that nCaP
D
CDDP 
at 12 mg/kg IT caused significantly more weight loss than nCaP
D
 IT (P < 0.05) (Figure 2.18 B).  
The in vivo anti-tumor efficacy of the nCaP
D
CDDP was repeated using SCCVII tumors 
in CH3/HeJ mice. In an attempt to slow the growth of the tumors, animals were administered 
fewer cells, 4 x 10
4
  in a Matrigel basement membrane, subcutaneously.  Animals were enrolled 
into treatment groups when their tumors reached 160 ± 10 mm
3 
in size.  There were 6 animals 
per group. Groups were: CDDP IP (10 mg/kg), Saline IT (50 uL), CDDP IT (50 uL, 2.2 mg/kg) 
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and nCaP
D
CDDP IT (11 mg/kg).  Here CDDP IP at 10 mg/kg was the most effective at delaying 
tumor growth (Figure 2.19).  A one-way ANOVA was performed comparing the average tumor 
volume per group each day.  At day 6, CDDP IP was significantly more effective at delaying 
tumor growth than Saline and nCaP
D
CDDP at 11 mg/kg (P < 0.05) Figure 2.20 A.  Again the 
maximum observed weight loss per group was compared relative to the day it occurred on 
(Figure 2.20 A).  Importantly, we determined that nCaP
D
CDDP at 11 mg/kg caused significantly 
greater weight loss than CDDP IT (2.2 mg/kg) and Saline IT (P < 0.05), with two animal 
dropping below 15% weight loss (Figure 2.20 B).  Survival was also plotted for this study 
(Figure 2.21).  CDDP IP at 10 mg/kg allowed for the longest survival times at 15 days post-
treatment.  Most animals were euthanized due to tumor volume exceeding nearing 2 cm in 
diameter and/or due to necrosis.   
2.3.6 In Vitro Cytotoxicity Assessment of Darvan, due to Toxicity Shown In Vivo 
The purpose of local intratumoral administration of chemotherapy, i.e. IT, is to lessen systemic 
toxicity experienced by the animal or patient. Here the in vivo efficacy studies revealed 
unforeseen toxicity from nCaP
D
CDDP administered IT.  This is cause for concern about the 
formulation or a component within the formulation. We therefore examined the in vitro 
cytotoxicity of D (Figure 2.22 A). We found that doses of D found in nCaP
D
CDDP are cytotoxic. 
The IC50 value of D was 455 ug/mL and the concentration of D estimated to be in nCaP
D
CDDP 
in concentrations typically utilized for cytotoxicity studies is 564 ug/mL. We therefore believe 
animals experienced weight loss due to the D in the nCaP
D
CDDP in addition to the CDDP, 
though in cytotoxicity studies nCaP
D
CDDP is not more effective than CDDP alone.  
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To further examine the biological effects of D in nCaP
D
CDDP, we compared the 
cytotoxicity of nCaP
D
CDDP to CDDP, Aq CDDP and microCaPCDDP to SCCVII (murine 
HNC), FaDu (human CDDP resistant HNC) and A2780cis (human ovarian CDDP resistant 
cancer) cells (Figure 2.22 C-D).  The same trend was found for all three cell types, where 
nCaP
D
CDDP was significantly less cytotoxic than CDDP alone (P < 0.0001).  For A2780cis cells 
microCaPCDDP was significantly more cytotoxic than CDDP  (P < 0.0001). 
2.4 Discussion 
The research described in this chapter was an effort to validate the synthesis and resulting 
properties of nCaP
DCDDP, along with assessing it’s efficacy in a murine HNC model.  The long-
term goal of clinical usage of nCaP
D
CDDP for the treatment of HNC cannot be realized if the 
synthesis of nCaP
D
CDDP cannot be repeated with comparable batch to batch results. As the 
development of nanoparticle systems progress, it is essential to take into consideration the scale-
up of production from the bench top to clinical and eventually commercial scale.  The FDA has 
issued Guidance for Industry: Liposomal Drug Products and created a nanotechnology task force 
in an effort to stay ahead of the advancing technology.  Within the document they highlight the 
need for control of product manufacture to ensure a repeatable product during scale-up, as 
seemingly small processing parameters can drastically change the resulting product
114
.  In this 
study, we employ a bottom-up approach to form nCaP
D
CDDP, made by precipitation of calcium, 
phosphate, and sodium polyacrylate (D), which was then reacted with CDDP.  We found that 
from batch to batch nCaP
D
 differs in yield and particle size because of lack of control over the 
precipitation with manual addition of components. The variability in particle size likely 
contributes to the variability in drug loading.  We were able to minimize the variability by a 
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minor modification to the nCaP
D 
protocol.  Creation of a combined large batch of nCaP
D 
allowed 
for uniform nanoparticles, which resulted in uniform drug loading.   
In vitro release testing of controlled release parenteral dosage forms such as the locally 
administered nanoparticle suspension studied here are essential for quality control, product 
development, and in-vitro-in-vivo-correlation (IVIVC).  In comparison to solid oral dosage 
forms, extended or controlled release parenterals have complex physicochemical properties and 
are varied in their components and resulting release characteristics.  Due to these factors, there is 
currently no standard compendial method to examine in vitro release from controlled release 
parenterals, where many exist for oral dosage forms
115
.  The Federation International 
Pharmaceutique (FIP) / American Association of Pharmaceutical Scientists (AAPS) report on in 
vitro release testing of novel dosage forms specifies that release testing methods used to screen 
formulations may not be feasible to use for quality control, but should be reevaluated towards 
use of a compendial apparatus
116
.  The release testing methods used for liposomes and 
nanoparticle suspensions can be generally categorized into: (1) sample and separate
16,117
, (2) 
dialysis sac
84,118,119
, or (3) continuous flow
22
.  
Herein, we utilized two types of in vitro release testing.  First we used the dialysis sac 
method with a Float-a-Lyzer® device which is a commercially available “Ready-to-Use Dialysis 
Device.”  nCaPDCDDP suspension was loaded into the sac and submerged into release medium 
agitated via an orbital shaker, covered in a temperature controlled chamber.  Only 45% of bound 
CDDP released from nCaP
D
CDDP using the Float-a-Lyzer® device.  This method is quite 
commonly used for initial screening of drug release from nanoparticle formulations, but has 
several drawbacks.  Due to their high surface area and small particle size, nanoparticles can 
release drug rapidly.  When using a dialysis based method it is assumed that there is not a 
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significant resistance in diffusion of drug across the dialysis membrane.  Zambito, Pedreschi and 
Di Colo showed that diclofenac released near completely from chitosan nanoparticles within an 
hour into the medium within the dialysis sac, but the dialysis membrane limited diffusion into the 
receiving medium
120
.  Diclofenac has a similar molecular weight to CDDP used here, 296 versus 
300 g/mol, respectively.  This study used a significantly smaller molecular weight cut off than 
we used in our study, which may have less of an effect on diffusion, 12 kDa versus 100 kDa.  
Additionally, high variation can be found in this method for reasons including: limited agitation 
within the dialysis tubes and high density of nanoparticles in the small volume of the dialysis 
tube, slowing diffusion
121
.   
For these reasons, we sought a more accurate and repeatable method to perform in vitro 
release testing.  Bhardwaj and Burgess developed a novel dialysis adapter  to modify the United 
States Pharmacopoeia (USP) apparatus 4 for in vitro release testing of colloids
22
.  Where they 
showed the modified USP 4 apparatus could discriminate between different liposomal 
formulations where dialysis sac methods could not, likely due to sufficient agitation within the 
sample cell.  Also of importance, sample replicates had low variation.  Here we found the 
modified USP apparatus 4 allowed for 78% of CDDP bound to nCaP
D/2
CDDP to release.  A 
majority of the CDDP was released in the first 72 hours, with 59% of drug releasing in this time.  
Importantly, we determined the CDDP released from nCaP
D
CDDP was as cytotoxic as CDDP 
against SCCVII cells, meaning active CDDP is released from the formulation.   
CaP is inherently biocompatible, as it is a major constituent of bones and teeth
109,122
.  
When synthesized via wet precipitation, CaP will form microcrystals. These microcrystals 
effectively bind and release CDDP
14
, but cannot be easily injected using a 25G needle. 
Additionally, microparticles are too large to pass through the circulatory system
70,123
.  Here the 
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addition of sodium polyacrylate halts the precipitation process leading to nanoparticles 150 nm 
in diameter on average.  A polyacrylate formed the arms of a star shaped polymeric 
nanoconjugate to deliver CDDP, which was shown through in vitro cytotoxicity testing of the 
conjugate to be significantly less cytotoxic than CDDP alone against several types of cancer 
cells
124
.  Here similar results were found with nCaP
D
CDDP, but the lessened cytotoxicity was 
not as pronounced and we know the released CDDP is effective.  This lessened cytotoxicity we 
believe is due to the short time frame of the cytotoxicity test, where free drug can readily diffuse 
into cells and nanoparticles would require drug to release or cellular uptake to cause cell death. 
Additionally, it has been shown that positively charged particles are more readily taken up by 
cells
95
 and nCaP
D
CDDP is negatively charged thus limiting cellular uptake.  
The goal of intratumoral delivery of chemotherapy is to localize a higher dose of drug at 
the tumor site while causing less systemic toxicity, for enhanced tumor reduction. That is the 
focus of our delivery mechanism. Many other nanoparticle formulations are administered 
systemically and hypothesized to enhance drug delivery based on the EPR effect
76
.  This method 
has proven effective for some formulations resulting in approval by the FDA. Doxil
®
 is an FDA 
approved liposomal formulation of doxorubicin. Doxil is readily used clinically to treat recurrent 
ovarian and relapsed multiple myeloma
73
. STEALTH® liposomal CDDP (SPI-77), using the 
same liposomal formulation as found in Doxil, was quickly entered into several clinical trials in 
patients with advanced cancers, finding no clinical efficacy because drug could not release from 
the liposome in vivo
78,79,125–127
. These findings highlight the significant problem of insufficient 
characterization of nanoparticle system components and their interactions with carried drug both 
physico-chemically and biologically prior to clinical efficacy testing. Importantly, the 
nanoparticle materials should not incur long-term deleterious effects on the patient. Patients 
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treated with SPI-77 incurred a significant increase in cholesterol (lipid) levels. Similarly, Doxil
® 
is not recommended for patients with a history of heart disease due to lipid load associated with 
treatment.  
The toxicity experienced by animals treated with 11 mg/kg nCaP
D
CDDP was not 
expected.  Though not significantly, the toxicity surpassed that of 10 mg/kg systemic CDDP. The 
overall goal of intratumoral delivery of CDDP via nCaP
D
CDDP was to diminish systemic 
toxicity experienced.  This prompted cytotoxicity testing of D alone, which showed that at 
concentrations found in nCaP
D
CDDP, D is cytotoxic itself.  This explains the toxicity experience 
by the animals in the efficacy study.  
Another noteworthy point of discussion is that SCCVII tumors are extremely aggressive. 
Within 10 days following vehicle treatment animals needed to be euthanized due to excessive 
tumor growth as per the Animal Care Committee guidelines at UCHC. This was found in other 
labs as well
63,128
.  Even with CDDP at the MTD tumors grew frenetically causing loss of animals 
in the treatment group after as little as 10 days.  In vitro SCCVII cells are considered a CDDP 
sensitive cell line, yet in vivo their aggressive phenotype overcomes any CDDP sensitivity. For 
future studies evaluating new therapeutics a less aggressive model would be better to use to limit 
large tumor burden and extend animal survival in negative control groups.   
2.5 Conclusions 
This study showed nCaP
D
CDDP can be made with batch to batch repeatability and retains 
particle size and biological activity after 3 years of storage.  The CDDP released from 
nCaP
D
CDDP is as biologically active as freshly prepared CDDP, in vitro.  In vivo nCaP
D
CDDP 
was ineffective at delaying tumor growth in comparison to a lower dose of CDDP administered 
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IT.  IT delivery of CDDP was repeatedly effective at delaying tumor growth of the very 
aggressive SCCVII tumors. This finding may have clinical relevance and will be studied further.  
From these studies it was determined that D is an effective stabilizer of CaP, but negatively 
impacts biological activity of CDDP and is toxic. For these reasons, other stabilizers will be 
researched for the nCaPxCDDP delivery system.  
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Figure 2.1 Molecular structure of sodium polyacrylate (Darvan® 811, D). 
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Figure 2.2 Graphic representation of nCaPxCDDP synthesis. Steps follow from left to right. 
After the final wash with KPB, particles are resuspended in sterile, deionized water. 
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Figure 2.3 The nanoparticle synthesis method represented in Figure 2.2 resulted in large batch to 
batch variability of particle size and drug loading. The nCaPDCDDP synthesis procedure was 
modified to achieve a more uniform nCaPD, prior to CDDP binding. This is a graphic 
representation of the modifications to the nCaPxCDDP synthesis steps. Three 1 L batches were 
made and pooled prior to washing. The pooled nCaPD was washed, resuspended in CDDP 
binding solution and split into three tubes for overnight binding.  
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Figure 2.4 TEM images (A) nCaPD deposited directly on the grid, and (B) nCaPDCDDP directly 
deposited on the grid, showing 20-30 nm particles agglomerated into larger clusters of particles 
120-180 nm in diameter. 
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Figure 2.5 X-ray diffraction spectra (Cu radiation, λ =1.54184 Å) of lyophilized nCaPD (top 
solid line) compared to hydroxyapatite standard (JCPDS, #09-0432) (bars). The match between 
the broad peaks of the nCaP
D
 with the standard indicates it is poorly crystalline hydroxyapatite. 
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Figure 2.6 In vitro release testing shows initial burst release over first 24 hours that tapers as 
release continues. Cumulative CDDP released is plotted using the left y-axis, percent CDDP 
released using right y-axis. (A) Released CDDP from nCaP
D
CDDP using a Float-a-Lyzer device 
with Mw cutoff of 100 kDa released into PBS, pH 6.8 to mimic acidic tumor microenvironment. 
(B) Released CDDP from nCaP
D/2
CDDP using a USP apparatus 4 modified with a dialysis 
adapter, Mw cutoff of 100 kDa released into PBS, pH 6.8. 
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Figure 2.7 Cytotoxicity testing analysis using an MTS assay against SCCVII cells. (A) 
Demonstration of typical four parameter logistic curve fit for CDDP data. (B) The highest 
concentrations of nCaP
D
CDDP in the assay interfere with absorbance readings at 490 nm. To 
correct for this, cells treated with the same concentration of nCaP
D
CDDP over the same time 
period are read on the plate reader without the addition of CellTiter 96® AQueous One reagent, 
labeled as Background. These average background absorbance readings are subtracted from the 
Original, to find the Corrected curve. The Corrected curve is used for IC50 determination. 
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Figure 2.8 Assessment of nCaP
D
 cytotoxicity measured at 490 nm from MTS assay against 
SCCVII cells. Arrow shows the concentration of nCaP
D
 in nCaP
D
CDDP at its IC50 value 
relative to CDDP. nCaP
D
 is not cytotoxic atIC50 value of nCaP
D
CDDP. 
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Figure 2.9 (A) Cytotoxicity curves of CDDP, Aq CDDP, nCaP
D
CDDP (R) and nCaP
D
CDDP. 
(B) Calculated IC50 values from cytotoxicity curves in A, where data represents 4 replicates. 
This data demonstrates that CDDP released from nCaP
D
CDDP is as cytotoxic as CDDP and Aq 
CDDP. nCaP
D
CDDP is significantly less cytotoxic than CDDP, Aq CDDP and released CDDP 
(P < 0.0001). 
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Figure 2.10 Stability studies. Freshly prepared nCaP
D
CDDP was compared to batches that had 
been stored for 2 (nCaP
D
CDDP 5-11-09) and 3 years (nCaP
D
CDDP 9-8-08). Particle size, drug 
loading and IC50 values against SCCVII cells of nCaP
D
CDDP were found to vary significantly 
with time stored. (A) Average particle size of stored batches was significantly larger than freshly 
made batch of nCaP
D
CDDP, ~22% larger (P < 0.0001). (B) Drug loading varied significantly 
from a freshly made batch of nCaP
D
CDDP for one of the two stored batches tested by ~25% (P < 
0.05). (C) IC50 value of batch stored for three years was significantly less cytotoxic than freshly 
made batch (P < 0.0001). 
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Figure 2.11 Effects of reducing D stabilizer concentration by half. To determine if less D 
could be utilized to stabilize nCaP, half the concentration was examined. (A) Average particle 
size of nCaP
D/2
CDDP is significantly smaller than nCaP
D
CDDP (P = 0.0213). (B) Drug loading 
of nCaP
D/2
CDDP is significantly greater than nCaP
D
CDDP (P = 0.0056). (C) IC50 value of 
nCaP
D/2
CDDP was not significantly different from nCaP
D
CDDP against SCCVII cells. 
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Figure 2.12 Batch to-batch variability assessment.  Three separate batches of nCaP
D
CDDP 
were made using exactly the same method. Although particle size was not significantly different 
from batch to batch, drug loading and IC50 values were. (A) Average particle size of three 
batches of nCaP
D
CDDP. (B) Each batch had significantly different drug loading than the next (P 
< 0.0001). (C) IC50 value of batch two is significantly higher than the other two batches against 
SCCVII cells (P < 0.001). (D) Yield varied from batch to batch, before and (E) after CDDP 
binding. 
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Figure 2.13 Following minor modifications to the nCaP
D
CDDP outlined in Figure 2.3 synthesis 
variation in drug loading and IC50 values were mitigated. (A) Average particle size of three 
batches of nCaP
D
CDDP made using modified method. Batch C was significantly smaller than 
the others, but it was only 3% smaller, which is typically acceptable deviation. (B) Differences in 
drug loading from batch to batch were mitigated with minor modifications to the synthesis and 
binding procedure. (C) Differences in IC50 value against SCCVII cells from batch to batch was 
also mitigated.  
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Figure 2.14 Maximum tolerable dose of nCaP
D
CDDP was conducted on CH3/HeJ mice bearing 
SCCVII tumors. nCaP
D
CDDP was administered once intratumorally. Weight loss was monitored 
every other day following treatment and shown for each animal. The legend indicates the animal 
number. (A) The 10 mg/kg dose was well tolerated.  (B) The 14 mg/kg dose caused weight loss 
down to 13%, but the animals recovered. (C) The 18 mg/kg dose caused one animal to drop to 
13% weight loss and was euthanized due to weight loss and tumor necrosis. (D) The 23 mg/kg 
dose caused one animal to drop below the 15% weight loss threshold. 
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Figure 2.15 A maximum tolerable dose study for the nCaP
D
CDDP was conducted on CH3/HeJ 
mice and compared to the free drug without nanoparticles. Drug was administered once 
subcutaneously. Weight loss was monitored every other day following treatment (A) The 9 
mg/kg dose nCaP
D
CDDP was well tolerated. (B) The 18 mg/kg dose nCaP
D
CDDP caused 
weight loss beyond 15%. (C) The 23 mg/kg dose nCaP
D
CDDP caused all animals to drop below 
the 15% weight loss threshold. (D) The 27 mg/kg dose nCaP
D
CDDP caused all animals to drop 
below the 15% weight loss threshold. (E) The 9 mg/kg CDDP was well tolerated. 
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Figure 2.16 Efficacy study of nCaP
D
CDDP was conducted on CH3/HeJ mice bearing SCCVII 
tumors. Animals were treated once when their tumor volume reached 120 ± 20 mm
3
. Each graph 
shows individual tumor volume (mm
3
) vs days post treatment for each animal in the group. The 
legend indicates the animal number. (A) Negative control, saline IT, did not delay any tumor 
growth. (B) Negative control, nanoparticles without drug IT, no significant tumor growth delay 
was seen. (C) Positive control, 6.5 mg/kg CDDP IP, was also not effective. (D) Positive control, 
6.5 mg/kg CDDP IT, to which response was split between near complete response and nearly no 
response. (E & F)
 
nCaP
D
CDDP IT at two different doses (6.5 and 12 mg/kg). Neither 
significantly delayed tumor growth 
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Figure 2.17 Efficacy study of nCaP
D
CDDP was conducted on CH3/HeJ mice bearing SCCVII 
tumors. Animals were treated once when their tumor volume reached 120 ± 20 mm
3
 and 
compared to 9 mg/kg CDDP. Tumor volume, grooming and weight loss were monitored every 
other day following treatment.  The graph shows average tumor volume (mm
3
) for each 
treatment group versus days post treatment.  The negative control Saline IT (20 uL) had no effect 
on tumor growth. nCaP
D
 (10 uL) had no effect on tumor growth. Free drug at 6.5 mg/kg CDDP 
intraperitoneally delayed tumor growth. 6.5 mg/kg CDDP caused tumors to stop growing or 
disappear in 50% of animals treated.  12 mg/kg nCaP
D
CDDP did not significantly delay tumor 
growth.  6.5 mg/kg nCaP
D
CDDP did not significantly delay tumor growth. 
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Figure 2.18 Efficacy and toxicity study of nCaP
D
CDDP was conducted on CH3/HeJ mice 
bearing SCCVII tumors. Animals were treated once when their tumor volume reached 120 ± 20 
mm
3
. Tumor volume, grooming and weight loss were monitored every other day following 
treatment. The average weight loss was determined for each group on each day following 
treatment. From that, the maximum weight loss for each treatment group was determined. (A) 
The table shows for each treatment group the maximum percent weight loss, the standard 
deviation and the day following treatment the weight loss occurred on. (B) At day 6 following 
treatment CDDP IT at 6.5 mg/kg was the most effective treatment for the delay of tumor growth 
(P < 0.05). 6.5 mg/kg nCaP
D
CDDP was significantly less effective at delaying tumor growth 
than CDDP IT at 6.5 mg/kg. (C) Is a graphical representation of tabulated values in A. 12 mg/kg 
nCaP
D
CDDP caused the most significant weight loss overall.  
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Figure 2.19 A repeated efficacy study of nCaP
D
CDDP was conducted on CH3/HeJ mice bearing 
SCCVII tumors. Animals were treated once when their tumor volume reached 160 ± 10 mm
3
 and 
compared to 10 mg/kg CDDP IP. Tumor volume, grooming and weight loss were monitored 
every other day following treatment. The graph shows average tumor volume (mm
3
) versus days 
post treatment (6 animals/group). The negative control Saline IT (50 uL) had no effect on tumor 
growth. IP CDDP (10 mg/kg) delayed tumor growth, but ultimately was not effective at stopping 
growth of SCCVII tumors. 
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Figure 2.20 Repeated efficacy and toxicity study of nCaP
D
CDDP was conducted on CH3/HeJ mice 
bearing SCCVII tumors. Animals were treated once when their tumor volume reached 160 ± 10 mm
3
 and 
compared to 10 mg/kg CDDP IP. Tumor volume, grooming and weight loss were monitored every other 
day following treatment. The average weight loss was determined for each group on each day following 
treatment. From that, the maximum weight loss for each treatment group was determined. (A) The table 
shows for each treatment group the maximum percent weight loss, the standard deviation and the day 
following treatment the weight loss occurred on. (B) CDDP IP at 10 mg/kg was the most effective 
treatment for the delay of tumor growth (P < 0.05). A dose of 11 mg/kg nCaP
D
CDDP was significantly 
less effective at delaying tumor growth than CDDP IP at 10 mg/kg. (C) Graphical representation of A. 
The 11 mg/kg nCaP
D
CDDP IT caused the most significant weight loss overall.  
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Figure 2.21 Survival curve for the repeated murine HNC animal model efficacy study shown in 
Figure 2.19.  Survival was defined as > 15% weight loss, tumor diameter > 2 mm, or inability to 
groom.  CDDP IP at 10 mg/kg was the most effective at prolonging survival of the mice.  
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Figure 2.22 Darvan ® 811 is cytotoxic at concentrations found in nCaP
D
CDDP and inhibits 
CDDP cytotoxicity. (A) Cytotoxicity curve of D against SCCVII cells. The arrow indicates D 
concentration in nCaPDCDDP at top concentration used for IC50 determination (564 ug/mL). 
IC50 values from cytotoxicity curves of CDDP, Aq CDDP, nCaP
D
CDDP and microCaPCDDP 
against: (B) SCCVII (C) A2780cis and (D) FaDu cells. 
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Chapter 3 
Sodium Citrate Stabilized Calcium Phosphate Nanoparticles for the Delivery of 
Cisplatin 
3.1 Introduction 
Head and neck cancer (HNC) patients suffer from many serious side-effects due to treatments 
including severe mucositis and complications with eating and talking
29
. If the tumor is in close 
proximity to vital anatomy, like the carotid artery, surgery is very dangerous and often 
impossible. For patients with these non-resectable tumors chemo-radiation is the standard of 
care, but the 5 year relative survival rate for is only 35%
129
. There is a desperate need for better 
localized treatments for HNC patients. 
Calcium phosphate is an attractive inorganic material for drug delivery because it is 
biocompatible, resorbable and relatively inexpensive to manufacture
65,66,130,131
. Calcium 
phosphate is an effective carrier for drugs and genetic material, that is readily made via 
precipitation, dissolves in acidic conditions, does not incite an immune response and is non-
toxic
15,67,89,96,109,132
. Precipitation of calcium phosphate will result in aggregated microcrystals 
unless a stabilizer is added to halt crystal growth and limit aggregation
100
. In Chapter 2, we 
showed sodium polyacrylate (Darvan ® 811) is cytotoxic in vitro and caused toxicity to animals 
as measured by weight loss when administered as a local injection of nCaP
D
CDDP  This chapter 
describes the use of sodium citrate to stabilize calcium phosphate for the delivery of CDDP. 
Sodium citrate is a known stabilizer of calcium phosphate and is on the Generally Regarded as 
Safe (GRAS) list from the Food and Drug Administration
21,133,134
. The molecular structure of 
sodium citrate is shown in Figure 3.1. Sodium citrate stabilized calcium phosphate nanoparticles 
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carrying CDDP (nCaP
CIT
CDDP) were physically characterized, tested for in vitro cytotoxicity 
and examined for in vivo intratumoral anti-tumor efficacy against a mouse model of human head 
and neck cancer. 
3.2 Materials and Methods 
3.2.1 Materials 
The CaCl2 (Sigma C4901), K2HPO4 (Sigma S1804), C6H5Na3O7 2H2O (Sodium Citrate, Sigma 
P3786), Pt(NH3)Cl2 (CDDP, Sigma P4394), and AgNO3 (Silver Nitrate, Sigma S6506) used to 
prepare the nanoparticles were all purchased from Sigma-Aldrich, (St. Louis, MO).  Aq-CDDP 
was prepared as described previously [1].  BD Matrigel™ for cell injections was purchased from 
BD Biosciences, (San Jose, CA). 
Murine squamous cell carcinoma of the head and neck, SCCVII, human hypopharyngeal 
carcinoma, FaDu cells from ATCC and human CDDP resistant ovarian cancer A2780cis cells 
were used for intro cytotoxicity evaluation of the nanoparticles. FaDu cells were used for in vivo 
anti-tumor efficacy. SCCVII cells were maintained as previously mentioned. FaDu cells were 
maintained in MEM (Gibco 10370) containing 10% heat-inactivated FBS, 1 mM sodium 
pyruvate (Invitrogen 11360), 2 mM L-glutamine (Invitrogen 25030), 1% penicillin streptomycin.  
The C3H/HeJ and Nu/J female mice were purchased from Jackson Laboratory, (Bar 
Harbor, ME) and used for studies at 6-8 weeks of age. 
3.2.2 nCaP
CIT
CDDP Production and Physical Characterization 
nCaP
CIT
CDDP synthesis was based on a previously reported method for nCaPCDDP
16
. To make 
the nCaP
CIT
 equal volumes of 30 mM CaCl2 and 30 mM K2HPO4 + 20 mM citrate were mixed by 
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adding the phosphate/citrate solution to the calcium and allowed to precipitate for 10 minutes 
with stirring.  Nanoparticles were collected via centrifugation (12000 rpm for 45 min) and 
washed once with MilliQ ® water. The particles were then allowed to adsorb Aq-CDDP for 20 
hours. The concentration of the CDDP was determined by inductively coupled plasma-optical 
emission spectroscopy (Perkin Elmer® Optima™ 5300 DV, ESIS Inc., Cromwell, CT). 
Following binding, the particles were collected via centrifugation, rinsed twice with MilliQ ® 
water to remove unbound Aq-CDDP and diluted 2x with 20 mM citrate solution to make a 
suspension that was injectable through a 25 gauge needle.  All solutions/liquids during the 
synthesis process were sterile-filtered with a 0.2 μm filter.  The nCaPCITCDDP suspension was 
stored at room temperature and shielded from light.   
Aq-CDDP content within the nanoparticles was determined by inductively coupled 
plasma-optical emission spectroscopy (Perkin Elmer® Optima™ 5300 DV, ESIS Inc., 
Cromwell, CT) on samples of known volume dissolved in 1N of HCl. Particle size analysis 
(PSA) was performed via dynamic light scattering technique using a 90 Plus Particle Sizer 
(Brookhaven Instruments, NY). Samples were prepared by sonicating the particle suspension and 
diluting the suspension 12x in MilliQ ® water.  The morphology and size of the particles were 
observed by using a Hitachi H-7650 transmission electron microscope (TEM). TEM samples 
were prepared by sonicating the particle suspension and diluting the suspension 26x in 10 mM 
citrate solution then 10x in 70% ethanol. A 5 uL sample was placed on a formvar carbon coated 
300 mesh Cu grid. Sample sat for 1min and then any excess solution was removed using filter 
paper. Prior to imaging the sample completely dried in air for 5 min.  Samples were imaged at 80 
kV with the TEM.  X-ray diffraction (XRD) was used to determine changes in crystallinity with 
addition of citrate stabilizer and to compare dry vs wet nCaP
CIT
. Samples of lyophilized calcium 
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phosphate without citrate (microCaP), lyophilized nCaP
CIT
 and wet nCaP
CIT
 were analyzed using 
a Bruker D2 Phaser. 
3.2.3 nCaP
CIT
CDDP In Vitro Drug Release Studies  
In vitro drug release studies were performed using ready to use dialysis devices, (Float-A-
Lyzer® G2, Spectrum Laboratories Inc., Rancho Dominguez, CA), with a molecular weight cut 
off of 100 kD.  0.55 mL of particle suspension was loaded in to the dialysis device and placed in 
22 mL of 10 mM PBS.  The pH of the PBS was adjusted to 6.8 to mimic an acidic tumor 
microenvironment.  The samples were capped, placed on an orbital shaker, and incubated at 
37°C.  Release samples were drawn at 1h, 6h, 1d, 3d, 5d, 7d, and 14d.  At each time point 5 mL 
of release solution was taken and replaced with 5 mL of fresh PBS.  CDDP content in the release 
solution was determined by inductively coupled plasma-optical emission spectroscopy (Perkin 
Elmer® Optima™ 5300 DV, ESIS Inc., Cromwell, CT).   
3.2.4 Cytotoxicity 
Cytotoxicity experiments were conducted using FaDu and SCCVII cells plated in 96 well plates 
at 60,000 and 20,000 cells/mL, respectively with 50 uL suspension per well. Cells were allowed 
to proliferate for 24 hours following which drug was added in 50 uL volumes. The following 
groups were examined with top concentration tested in parentheses: Citrate ( 10 mM), nCaP
CIT
 
(to match nCaP
CIT
 in nCaP
CIT
CDDP ), (CDDP in saline (405 ug/mL), aquated CDDP (466 
ug/mL), 20 mM citrate reacted with to Aq CDDP (Aq CDDP-CIT) (458 ug/mL), nCaP
CIT
CDDP 
(500 ug/mL), and nCaP
CIT
CDDP release 3d (R) (119 ug/mL). Each group was serially diluted 
1:3 across the plate using PBS. Cells were assayed 48 h after drug addition using in an MTS 
assay (CellTiter 96® AQueous One, G3580, Promega Corp., Madison, WI), where metabolic 
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activity was determined using a Spectramax Plus
384 
Spectrophotometer (Molecular Biosciences, 
Sunnyvale, CA) at an absorbance of 490nm. To determine the IC50 (50% inhibitory 
concentration) a non-linear regression curve fit analysis was performed with at least four 
replicates per group.   
3.2.5 nCaP
CIT
CDDP In Vivo Maximum Tolerable Dose Study 
A maximum tolerable dose (MTD) study was performed in 6 month old C3H/HeJ female mice 
without tumors (1-4 mice/group) as follows. The MTD was defined for the purposes of this study 
as the maximum dose that could be administered to a mouse that will result in less than 15% 
weight loss.  Each mouse received one, intraperitoneal (IP) injection of the nanoparticle 
suspension via a 25-gauge needle; groups included: 10, 20, 30, and 40 uL injections of 
nCaP
CIT
CDDP at a CDDP concentration of 16.7 mg/mL.  These volumes result in average doses 
of 7.4 mg/kg, 13.3 mg/kg, 20.8 mg/kg, and 24.5 mg/kg respectively, based on individual mouse 
weight and CDDP concentration of the nanoparticle suspension.  Mouse weight was monitored 
daily for eight days, (by day 8 all mice had recovered from the normal initial weight loss seen 
with CDDP doses in the first few days, or had exceeded 15% weight loss).  Mice exceeding 15% 
weight loss were euthanized. 
3.2.6 FaDu Tumor Take Rate in Nu/J Mice 
To assess the growth parameters of FaDu tumor initiated in Nu/J mice two tumor take rate 
studies were performed. This was performed to ensure that tumors will growth at a steady pace, 
without growing too fast causing necrosis or too slow such that they regress on their own. The 
first study used a BD Matrigel™ to cells in base media ratio of 80:20. Four mice were used per 
groups and the groups were: 8 x 10
5 
cells in a 200 uL volume injection or 2 x 10
5 
cells in a 100 
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uL injection, in the right rear flank via a 25-gauge needle.  Animals were monitored every other 
day for 15 days following inoculation.  
The second tumor take rate study was conducted again using a 80:20 ratio of Matrigel : 
cell suspension. Here groups were: 5 x 10
6 
cells in 200 uL injection (5 animals) and 2 x 10
6 
cells 
in 200 uL injection (3 animals), in the right rear flank via a 25-gauge needle.  Animals were 
monitored every other day for 15 days following inoculation.  
3.2.7 nCaP
CIT
CDDP In Vivo Anti-Tumor Efficacy and Toxicity Studies 
Two efficacy and toxicity studies were performed using FaDu cells in Nu/J mice. The first study 
included 33 mice inoculated with 2x10
6
 FaDu cells in 100μL of a 70 : 30 ratio of BD Matrigel™ 
: cell-media in the right rear flank via a 25-gauge needle.  A total of 33 female, 8 week old, Nu/J 
mice were included in the study, (4-6 mice/group, 6 groups). Tumors were measured daily using 
digital calipers to calculate the tumor volume as follows:  V = (W)
2
 * L * 0.4.  Tumors were 
treated once with: 10 mg/kg CDDP IP,  30 µL of saline IT, 20 µL of nCaP
CIT
 IT(without CDDP), 
1.4 mg/kg CDDP IT, 13.7  mg/kg nCaP
CIT
CDDP IT or 20.7  mg/kg nCaP
CIT
CDDP IT, when 
tumor volume reached 120 ± 20 mm
3
.   
In the repeat efficacy and toxicity study Nu/J mice were inoculated with 2x10
6
 FaDu cells 
in 100μL of a 60 : 40 ratio of BD Matrigel™ : cell-media in the right rear flank via a 25-gauge 
needle.  A total of 28 female, 5 week old, Nu/J mice were included in the study, (7 mice/group, 4 
groups). Tumors were measured daily using digital calipers to calculate the tumor volume as 
follows:  V = (W)
2
 * L * 0.4, where W = width, L = length, and V = volume. 
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Tumors were treated once, intratumorally (IT), with either 30 µL of saline, 30 µL of nCaP
CIT
 
(without CDDP), 1.4 mg/kg CDDP in saline (CDDP IT), or 10 mg/kg nCaP
CIT
CDDP, when 
tumor volume reached 140 ± 14 mm
3
.   
For both studies systemic toxicity was evaluated by weight change and overall 
grooming/appearance.  Tumor volume and mouse weight were monitored at least every other 
day. Mice were euthanized due to significant weight loss (> 15%), a tumor length measurement 
greater than 20 mm, or completion of the study (day 30).  All animal experimental procedures 
were approved by the Animal Care and Use Committee of the University of Connecticut Health 
Center, (Farmington, CT). 
3.2.8 Statistical Analysis  
Statistical analysis was performed using an unpaired t-test or Tukey one-way ANOVA, as 
indicated in the methods.  A P-value of less than 0.05 was considered statistically significant.  
Data is presented as a mean value with its standard deviation indicated (mean + SD).   
3.3 Results  
3.3.1 Physical Characterization of nCaP
CIT
CDDP 
A diagram of the nCaP
CIT
CDDP composition is shown in Figure 3.2.  Positively charged Aq 
CDDP electrostatically binds to negatively charged nCaP
CIT
 to make nCaP
CIT
CDDP.  Release of 
Aq CDDP is achieved when nCaP
CIT
CDDP is placed in in vitro or in vivo conditions in the 
presence of chloride ions which cause the re-formation of native CDDP.  Transmission electron 
microscopy (TEM) (Figure 3.3 A) and particle size analysis via dynamic light scattering (Figure 
3.3 B) showed that nCaP
CIT
CDDP in suspension form small aggregates with an average size of 
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180.6 + 19.5 nm.  Average drug loading of the suspension is 158.7 + 11.6 µg CDDP/mg 
nCaP
CIT
.  These results, in addition with polydispersity, are summarized in Table 3.1.  XRD 
comparing nCaP
CIT 
as a wet suspension, nCaP
CIT 
lyophilized and microCaP showed 
nCaP
CIT
CDDP is poorly crystalline with the major peak occurring at 30º corresponding well with 
hydroxyapatite (HA) while microCaP was more crystalline in nature resembling brushite and 
poorly crystalline HA (Figure 3.4) 
113,135
. The comparison of microCaP with both wet and dry 
nCaP
CIT 
 clearly demonstrate that crystal growth of CaP was halted by the addition of citrate, 
creating nanoparticles with no long order crystal structure. 
3.3.2 nCaP
CIT
CDDP In Vitro Release Studies  
The release profile of the nCaP
CIT
CDDP in PBS, pH 6.8, at 37° C can be seen in Figure 3.5. 
nCaP
CIT
CDDP has continuous in vitro release. A burst release of CDDP was exhibited in the first 
24 h, with slower, continuous release out to day 14.  Total percent CDDP release after 14 days is 
27% based on total CDDP bound.  
3.3.3 Cytotoxicity 
FaDu cells were used to determine the cytotoxicity of nCaP
CIT
CDDP, nCaP
CIT
CDDP, citrate, Aq 
CDDP-CIT, CDDP and Aq CDDP.  Non-linear regression curve fit analysis of each of these 
treatments is shown in Figure 3.6 A-F.  nCaP
CIT
 is not cytotoxic as all concentrations tested had 
comparably high absorbance readings (Figure 3.6 D). Citrate alone caused some toxicity at a top 
dose of 10 mM (Figure 3.6 C). The in vitro cytotoxicity of nCaP
CIT
CDDP and the released 
CDDP from nCaP
CIT
CDDP were determined with FaDu and SCCVII cells using an MTS assay. 
The 50% inhibitory concentrations (IC50) are plotted in Figure 3.7. CDDP released from 
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nCaP
CIT
CDDP has the same cytotoxicity as CDDP alone and Aq-CDDP. Sodium-citrate when 
reacted with Aq CDDP inhibits the cytotoxicity of Aq CDDP. 
3.3.4 FaDu Tumor Take Rate in Nu/J Mice  
Two tumor take rate studies were conducted in Nu/J mice. The first study used either 2 x 10
5 
or 8 
x 10
5 
cells per injection, both of which were determined to be insufficient for regular tumor 
growth (Figure 3.8 A. Tumors did not grow steadily and growth tapered after 10 days. The 
second tumor take rate study used 2 x 10
6 
or 5 x 10
6 
FaDu cells per injection (Figure 3.8 B).  The 
early shrinking of tumor volume is due to degradation of Matrigel. Once the Matrigel degrades 
tumor growth continues. 
3.3.5 nCaP
CIT
CDDP In Vivo Maximum Tolerable Dose Study 
A maximum tolerable dose (MTD) study was performed in C3H/HeJ mice without tumors, 
(Figure 3.9).  The MTD is defined as the maximum dose that can be administered to a mouse that 
will result in less than 15% weight loss and is a measure of systemic toxicity of the tested 
materials.  The maximum tolerable dose that can be administered to a C3H/HeJ mouse without 
experiencing significant weight loss (> 15%) is 13 mg/kg nCaP
CIT
CDDP IP. The conjugation of 
CDDP to nCaP
CIT
 allows for an increase in MTD compared to CDDP IP (MTD 10 mg/kg).  The 
results shown in Fig. 13.9 show the average weight loss for the 13.3 and 24.5 mg/kg 
nCaP
CIT
CDDP IP dose, in addition to the average weight loss of a 9 mg/kg CDDP IP dose 
performed in C3H/HeJ, female, 6 month old mice, but from a previous study.   
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3.3.6 nCaP
CIT
CDDP In Vivo Anti-Tumor Efficacy and Toxicity Studies 
The in vivo anti-tumor efficacy of the nCaP
CIT
CDDP was evaluated using FaDu human 
hypopharyngeal carcinoma tumors in Nu/J.  Nu/J mice were injected with 2x10
6 
Fadu cells in 
100 µL of 70% Matrigel™ 30% cells and media subcutaneously. Tumors were treated once with: 
10 mg/kg CDDP IP,  30 µL of saline IT, 20 µL of nCaP
CIT
 IT(without CDDP), 1.4 mg/kg CDDP 
IT, 13.7  mg/kg nCaP
CIT
CDDP IT or 20.7  mg/kg nCaP
CIT
CDDP IT, when tumor volume 
reached 120 ± 20 mm
3
.  The change in tumor volume and mouse weight was evaluated for 15 
days post treatment (Figure 3.10 A and B). Due to large standard deviations statistical 
differences were not detected between the treatment groups.  The average tumor volume for 
animals treated with 1.4 mg/kg CDDP IT was the lowest, with 10 mg/kg CDDP IP and 13.7 
mg/kg nCaP
CIT
CDDP.  
For the repeat efficacy and toxicity study , 5 week old, Nu/J mice (Jackson Laboratories) 
were injected subcutaneously with 2x10
6 Fadu cells in 100 µL of 60% Matrigel™ 40% cells and 
media. Tumors were treated intratumorally (IT) with varying doses of: saline, CDDP in saline, or 
nCaP
CIT
CDDP, once when tumor volume reached 140±14 mm
3
.  The change in tumor volume 
and mouse weight was evaluated for 30 days post treatment. 10 mg/kg nCaP
CIT
CDDP IT resulted 
in delayed tumor growth (Figure 3.11 A).  As expected, saline IT and nCaP
CIT
 IT (no CDDP) had 
no effect preventing tumor growth.  10 mg/kg nCaP
CIT
CDDP and CDDP were significantly more 
effective at slowing tumor growth than saline or nCaP
CIT
 (Tukey one-way ANOVA).  1.4 mg/kg 
CDDP IT was significantly most effective in inhibiting tumor growth.  For each treatment group, 
average mouse weight loss was not significant (> 15%), (data not shown). Toxicity of the 
nCaP
CIT
CDDP was also evaluated via survival (Figure 3.11 B).  During the anti-tumor efficacy 
study mice were euthanized due to weight loss greater than 15%, tumor necrosis, or having a 
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tumor width measurement of 20 mm or greater.  Mice treated with 1.4 mg/kg CDDP IT observed 
100% survival at day 30.  Mice treated with 10 mg/kg nCaP
CIT
CDDP IT resulted in 57% survival 
at day 30.   Both saline IT and nCaP
CIT
 IT observed 0% survival by day 30.  
3.4 Discussion 
These results show that sodium citrate is an effective stabilizer for calcium phosphate 
nanoparticles carrying CDDP enabling the delivery of a higher dose of CDDP compared to free 
CDDP administration with comparable toxicity to the treated animals. The in vitro drug release 
profile for nCaP
CIT
CDDP shows a maximum release of 27% of CDDP loaded onto the 
nanoparticles is released over the 14 day time period studied.  It was expected that 
nCaP
CIT
CDDP would be more effective at treating the tumors locally than a lower dose of free 
CDDP, however this was not found in this xenograft model of head and neck cancer. Ultimately 
no treatment successfully shrank tumors to their size at treatment nor caused remission, but the 
1.4 mg/kg dose of CDDP administered IT resulted in significantly smaller tumors than controls 
or nCaP
CIT
CDDP at 10 mg/kg.  This may be due to FaDu cells being moderately CDDP 
resistant
136,137
 combined with the larger tumor volume range at the start of treatment (up to 154 
mm
3
). We examined the biological activity of the CDDP released from nCaP
CIT
CDDP in a 
cytotoxicity assay, finding no statistically significant differences between CDDP released from 
nCaP
CIT
CDDP, CDDP and Aquated CDDP. 
 The in vitro release study conducted here was performed using a commercially available, 
“ready-to-use” dialysis sac device.  This is one of several general methods of studying drug 
release that are performed for nanoparticles, including: sample and separate, dialysis sac and 
flow through methods
116
.  This method was utilized as a screening method to determine if 
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biologically active drug released from the formulation and if so, approximately how much.  To 
mimic intratumoral conditions we utilized a release medium with pH 6.8
138
.  This step is 
insufficient for development of an in-vitro-in-vivo-correlation (IVIVC), as IVIVC for parenteral 
controlled release systems is challenging based on the in vivo site of administration
139,140
, here 
intratumoral.  Sink conditions were utilized for our studies and within a dense tumor, there is 
limited fluid available and likely sink conditions are not present.  At a workshop of the American 
Association of Pharmaceutical Scientists (AAPS), Food and Drug Administration (FDA) and 
United States Pharmacopoeia (USP) it was stated that a drug release of 80% is desirable from 
controlled release parenterals for both safety and the production of an economical dosage 
form
115
.  Here we were unable to achieve 80% release from nCaP
CIT
CDDP, this may be due to 
lack of sufficient agitation within the dialysis device and high nanoparticle content within the sac 
limiting release within and diffusion out of the sac into the release medium
120
.  An additional 
method we could have employed to overcome some of these pitfalls would be to perform reverse 
dialysis, where the nanoparticles would be suspended within the release medium in the large 
vessel and samples removed from within the dialysis sac.  This method would alleviate the 
challenge posed by nanoparticles being too concentrated within the dialysis sac
121
.  Further 
development of this formulation would require a more accurate and reproducible method of drug 
release testing.  A newly developed method, in Dr. Burgess’ lab at the University of Connecticut, 
incorporated a dialysis adapter into the flow through sample cell of a USP apparatus 4
22
.  They 
were able to discriminate between small variations in liposomal formulations and maintained 
minimal variability between replicates.  Additionally, this would be a step towards use of a 
compendial apparatus for in vitro release testing, which is more analogous to what is performed 
for oral dosage forms
141
.  
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The anti-tumor efficacy of the 1.4 mg/kg CDDP administered IT has not been previously 
published to our knowledge. This low IT dose of CDDP had not been reported to be sufficient 
for delayed tumor growth. The lowest reported dose for CDDP administered IT in a murine 
model is 5 mg/kg, which showed minimal tumor growth delays on the order of 3-5 days
61,142,143
.  
We confirmed this finding by repeating the animal study with the same results. Additionally, 
FaDu cells are considered a relatively CDDP resistant HNC cell line, with a published IC50 of 6 
µM (1.8 µg/mL) 
137
, and in our lab we found they were even more resistant with an average IC50 
of 13.3 µM (4 µg/mL). This is therefore an excellent model for comparison to HNC patients 
because it is estimated that 50% of patients with locally advanced HNC will recur with 
chemotherapy resistant cancer
29
. Intratumoral CDDP for the local treatment of HNC may be a 
viable alternative for non-resectable tumors, or partially resectable tumors. This further supports 
the need to develop an effective local delivery system for CDDP that allows for prolonged 
delivery of high local concentrations of biologically active CDDP. 
In our lab and others, one of the primary complications to the development of an effective 
delivery system is sufficient release of active drug that can penetrate through the tumor mass 
once released.  Many different approaches to local therapy for HNC patients have been 
researched.  Poly-Ɛ-caprolactone blended with poly(DL-lactide-co-Ɛ-caprolactone) sheets loaded 
with CDDP were examined in a model of murine HNC where partial surgical resection was 
combined with radiotherapy which found the polymer sheet with CDDP and radiotherapy 
significantly reduced tumor burden, but the polymer sheet with CDDP alone was not effective 
144
. These findings correlate well with many reports of CDDP as a radiosensitizer
61,63,145–147
. An 
injectable polymer, poly (sebacic acid-co-ricinoleic acid ester anhydride), for intratumoral 
delivery of CDDP was examined in a model of murine bladder cancer, where the polymer alone 
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inhibited tumor growth compared to untreated mice
143
.  The authors speculated the delayed 
tumor growth from polymer alone was due to physical injury to the tumor.  We examined 
nCaP
CIT
 alone IT, but did not cause any delay in tumor growth. We believe this is due to the 
superior biocompatibility of CaP as a drug carrier, compared to polymers that often have acidic 
degradation by-products.  
Nanoparticles for the local delivery of chemotherapy to a tumor have also been 
researched.  Li et al., examined block copolymer methoxy poly(ethylene glycol)-
polycaprolactone CDDP nanoparticles against a murine model of liver cancer finding when 
delivered IT, the particles were no more effective than CDDP IT at equivalent doses 
142
.  
Albumin microparticles carrying chemotherapeutic drug mitoxantrone were examined for IT 
efficacy against murine breast cancer where the microspheres were not able to increase the MTD 
for the carried drug nor were they more effective than free drug alone at increasing animal 
survival
148
.  One of the major advantages of a successful IT delivery system is the ability to 
deliver a higher dose of drug directly at the site of the tumor.  Theoretically the local delivery 
offers a therapeutic advantage by limiting systemic drug clearance and drug exposure to healthy 
tissues thereby decreasing systemic toxicity
57
.  Here we found that local delivery of very low 
doses, 14% of a standard systemic dose of 10 mg/kg for a mouse, of free CDDP was able to 
significantly delay tumor growth.  This is likely due to the ability of CDDP to more freely 
diffuse throughout the dense tumor tissue, versus the nanoparticles which are too large to move 
through the interstitial collagen barrier in solid tumors
82
. Achieving evenly distributed drug using 
a nanoparticle delivery system is an ongoing challenge for cancer treatment.  
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3.5 Conclusion 
In this study we were able to deliver higher doses of CDDP with nCaP
CIT
CDDP IT compared to 
systemic CDDP, with comparable toxicity.  nCaP
CIT
CDDP caused a significant delay in tumor 
growth compared to nCaP
CIT
 and saline controls, but was surpassed by free CDDP administered 
IT.  Although the anti-tumor efficacy of CDDP IT at 1.4 mg/kg is unexpected relative to the 
literature, it is very clinically relevant and therefore important to explore further.   
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Figure 3.1 Molecular structure of sodium citrate. 
 
 
Figure 3.2 Schematic representation of aquated CDDP binding and release from nCaP
CIT
CDDP. 
(A) From left to right, CDDP can be made into aquated CDDP, via a reaction with AgNO3.  
AgCl precipitate is removed via centrifugation and filtration, leaving a net positively charged 
aquated CDDP.  nCaP
CIT
 is negatively charged to bind the positively charge aquated CDDP, 
resulting in nCaP
CIT
CDDP.  (B) In a chloride rich environment, like within the body, a driving 
chloride ions act as a driving force for the release of aquated CDDP to reform native CDDP.  
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Table 3.1 Addition of sodium citrate to calcium phosphate precipitation results in nano-sized particles. 
 
 
Figure 3.3 Characterization of the nanoparticles. (A) TEM image of nCaP
CIT
CDDP, scale bar is 
100 nm. Arrow indicates spindle-like citrate molecules. Image shows 20-50 nm particles 
agglomerated into larger clusters of particles 120-180 nm in diameter (B) Particle size 
distribution of nCaP
CIT
CDDP, bar represents average particle size of 178 nm. 
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Figure 3.4 XRD of nCaP
CIT 
 suspension (nCaP
CIT
 wet), lyophilized nCaP
CIT 
(nCaP
CIT
 dry) and 
lyophilized CaP without citrate stabilizer added during precipitation (microCaP dry) shown from 
top to bottom (Cu radiation, λ =1.54184 Å).  The circles demonstrate major peaks of Brushite 
within microCaP.  This demonstrates that citrate halted the long order crystal growth when 
present during precipitation, compared to the crystalline peaks observed in microCaP that has no 
stabilizer present. For comparison hydroxyapatite standard (JCPDS, #09-0432) (bars) is shown.  
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Figure 3.5 nCaP
CIT
CDDP provides sustained delivery of CDDP in vitro.  Average percent 
CDDP release after 14 days is 27% based on total CDDP available for release.  Release studies 
were performed using Float-a-Lyzers ® in PBS, pH 6.8, at 37° C, molecular weight cutoff = 100 
kDa. 
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Figure 3.6 FaDu, human head and neck cancer cells were used to examine the in vitro 
cytotoxicity of: (A) CDDP (blue and red colors show replicates), (B) Aq CDDP, (C) Citrate, (D) 
nCaP
CIT
,
 
(E) Aq CDDP – CIT, and (F) nCaPCITCDDP. The highest concentrations of 
nCaP
CIT
CDDP in the assay interfere with absorbance readings at 490 nm. To correct for this, 
cells treated with the same concentration of nCaP
CIT
CDDP over the same time period are read on 
the plate reader without the addition of CellTiter 96® AQueous One reagent, labeled as 
Background. These average background absorbance readings are subtracted from the Original, to 
find the Corrected curve. The Corrected curve is used for IC50 determination. 
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Figure 3.7 Cytotoxicity test of nCaP
CIT
CDDP against (A) FaDu (human HNC) and (B) SCCVII 
(mouse HNC) cells in an MTS assay to determine the IC50 value of each treatment. These 
studies show that CDDP released from nCaP
CIT
CDDP (nCaP
CIT
CDDP (R)) has the same 
cytotoxicity as free CDDP, for both cell types. Reacting sodium-citrate with Aq CDDP 
significantly decreases the cytotoxicity of Aq CDDP, for both cell types (P < 0.05).  
nCaP
CIT
CDDP was significantly less cytotoxic than CDDP for both cell types (P < 0.05). 
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Figure 3.8 Tumor take rate studies performed in Nu/J mice using FaDu cells at two different 
concentrations injected in right rear flank of animals. Plots show average tumor volume  per 
group (mm
3
) vs number of days since injection of cells, error bars show standard deviation. A 
cell number of 2 x 10
6
 was deemed sufficient to initiate tumors, and 2 x 10
5 
or 8 x10
5 
cell number 
injections grew too slow.  (A) Cell number and injection volume were as follows: 8 x 10
5 
in 200 
uL or 2 x 10
5 
FaDu cells in 100 uL volume using Matrigel (4 animals/group). (B) Cell number 
injected per 200 uL volume: 5 x 10
6 
or 2 x 10
6 
FaDu cells in Matrigel (5 and 3 animals/group, 
respectively). 
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Figure 3.9 Weight loss over time with intraperitoneal injections in CH3/HeJ mice.  A dose 13 
mg/kg nCaP
CIT
CDDP IP is the maximum tolerable dose (MTD) that can be administered IP 
without experiencing significant weight loss (> 15%). Delivering CDDP using nCaP
CIT
 allows 
for an increase in MTD 13 mg/kg compared to CDDP IP (MTD 10 mg/kg). A dose of 24.5 
mg/kg nCaP
CIT
CDDP IP caused significant weight loss and therefore cannot be used for 
treatments. 
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Figure 3.10 Nu/J mice were injected with 2x10
6 
Fadu cells in 100 µL using Matrigel, 
subcutaneously. Tumors were treated with varying doses of: saline, CDDP, nCaP
CIT 
or 
nCaP
CIT
CDDP when tumor volume reached 120±20 mm
3
.  No significant differences in tumor 
volume were found between groups (A) Average tumor volume (mm
3
) per group vs. days post 
treatment. (B) Average percent weight loss for each treatment group. 
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Figure 3.11 A repeat efficacy testing of nCaP
CIT
CDDP in a mouse model of human HNC was 
conducted. Nu/J mice injected with 2x10
6 
Fadu cells in 100 µL using Matrigel, subcutaneously. 
Tumors were treated once tumor volume reached 140 ± 14 mm
3
. In this study a lower dose of 10 
mg/mg nCaP
CIT
CDDP was administered intratumorally. (A) Graph shows average tumor volume 
(mm
3
) per group versus days following treatment.  A 10 mg/kg dose of nCaP
CIT
CDDP resulted 
in delayed tumor growth.  There were significant differences between Saline and 10 mg/kg 
nCaP
CIT
CDDP, Saline and CDDP IT, and 10 mg/kg nCaP
CIT
CDDP and CDDP (P < 0.05). (B) 
Survival curve showing percent surviving animals versus days following treatment.  Survival 
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was defined as > 15% weight loss, tumor diameter > 2 mm, or inability to groom.  CDDP IT 
allowed for 100% survival to day 30 following treatment.  The 10 mg/kg dose of nCaP
CIT
CDDP 
allowed for 57% survival to day 30. NOTE: The legend applies to both graphs. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Jessica Lea Woodman – University of Connecticut, 2014 
 
83 
 
Chapter 4 
Carboxymethyl Hyaluronic Acid Stabilized Calcium Phosphate Nanoparticles for 
Delivery of Cisplatin 
4.1 Introduction 
Triple negative breast cancer (TNBC) patients have limited treatment options because their 
cancer does not present with hormone receptors that are effectively targeted for treatment in 
breast cancer
149
.  These patients could greatly benefit from a localized treatment that can reduce 
the tumor prior to surgical resection, with the goal of lessening chances for recurrence. In this 
study calcium phosphate nanoparticles (nCaP) were synthesized with carboxymethyl hyaluronic 
acid (CMHA) to determine if CMHA could simultaneously stabilize nCaP and target cancer 
cells.  CMHA is hyaluronic acid (HA) that has been modified to contain extra carboxylate groups 
which are known to interact with Ca and P ions in the during precipitation of CaP
134
 (Figure 4.1). 
Hyaluronic acid (HA) is a major component of the extracellular matrix, a glycosaminoglycan
150
 
and CD44 is a transmembrane molecule that is a major binding and homing receptor for HA. 
Therapy resistant breast cancer cells have a common phenotype of CD44
+
/CD24
low
. The 
presence of these cells in patients with triple negative breast cancer (TNBC) is a poor prognostic 
indicator and linked with recurrence
48
. Therefore the goal of this study was to determine if 
nCaP
CMHA
CDDP could effectively target and kill TNBC cells with the 
CD44
+
/CD24
low
phenotype. 
 
  
Calcium phosphate is an excellent biomaterial because it is biocompatible, resorbable and 
non-immunogenic
94,99,108
.  In Chapters 2 and 3, we found that both sodium polyacrylate (Darvan 
® 811) and sodium citrate effectively stabilize nCaP, but have inhibitory effects on the biological 
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activity of cisplatin (CDDP). Here we introduced carboxymethyl hyaluronic acid (CMHA) 
during the precipitation process of CaP, creating nCaP
CMHA
, with the goal of achieving both 
nCaP stabilization and biological targeting of CD44.  CDDP is an effective anti-cancer drug, but 
has dose limiting nephrotoxicity.  This study was the first to use carboxymethyl-HA (CMHA) to 
stabilize nCaP and simultaneously target CD44 expressing cells while carrying CDDP, 
nCaP
CMHA
CDDP.  nCaP
D
CDDP was used as a negative control for evaluating the targeting 
capacity of nCaP
CMHA
CDDP.  nCaP
CMHA
CDDP was physically characterized using: transmission 
electron microscopy (TEM), X-Ray diffraction, particle size analysis and in vitro drug release 
studies. The ability of CMHA and nCaP
CMHA
CDDP to bind CD44 was examined using surface 
plasmon resonance. Cytotoxicity of nCaP
CMHA
CDDP and the impact of CMHA on Aq CDDP 
were examined in vitro against both CD44- and CD44+ cell types. Lastly, an anti-tumor efficacy 
study was performed on a model of human therapy resistant TNBC with BT-474m cells.  
4.2 Materials and methods 
4.2.1 Materials 
Calcium lactate pentahydrate (Sigma C8356), K2HPO4 (Sigma S1804), Pt(NH3)Cl2 (CDDP, 
Sigma P4394), and AgNO3 (Silver Nitrate, Sigma S6506) used to prepare the nanoparticles were 
all purchased from Sigma-Aldrich, (St. Louis, MO).  Darvan® 811 was purchased from R.T. 
Vanderbilt Holding Company, Inc. (Norwalk, CT).  CMHA and HA for these studies was 
graciously supplied by Dr. Glenn Prestwich at the University of Utah. Aq-CDDP was prepared 
as described previously [1].  BD Matrigel™ for cell injections was purchased from BD 
Biosciences, (San Jose, CA). 
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Mouse fibroblast cells, NIH-3T3, were purchased from ATCC. They were maintained in 
DMEM high glucose (Gibco 11995) with 10% Fetal Calf Serum and 1% penicillin streptomycin. 
LMS, BT-474 and BT-474m cells were kindly provided by Dr. Bruce White at the University of 
Connecticut Health Center. BT-474 cells were maintained in DMEM/F12 (Gibco 11330) with 
10% FBS, 1% p/s and 1% insulin. LMS and BT-474m cells were maintained in DMEM/F12 
(Gibco 11330) with 10% FBS, 1% p/s. 
  J:Nu female mice were purchased from Jackson Laboratory, (Bar Harbor, ME) and used 
for studies at 6-8 weeks of age.  Female athymic nude mice, 6-8 weeks of age, were obtained 
from Charles River Laboratories International, Inc. (Wilmington, MA).  
4.2.2 nCaP
CMHA
CDDP Production and Physical Characterization 
nCaP
CMHA
CDDP synthesis was based on a previously reported method for nCaPCDDP
16
. To 
make nCaP
CMHA
, 30 mM Calcium lactate was added to the reaction vessel and mixing initiated. 
To which an equal volume of 30 mM K2HPO4  was added, immediately followed by 2% (w/v) 
CMHA (34 kDa) in water at 20% of the total volume of precipitation. Mixing continued for 10 
minutes.  Nanoparticles were collected via centrifugation (12000 rpm for 45 min) and washed 
once with MilliQ ® water. The particles were then allowed to adsorb Aq CDDP for 20 hours.  
The nanoparticle s were protected from light on a heated rocker (LAB-LINE® thermorocker, 
Barnstead Thermolyne, Dubuque, IA) maintained at 37ºC.  Following binding, the particles were 
collected via centrifugation, rinsed with 10 mM KPB to remove unbound Aq CDDP and diluted 
to approximately 175 mg nCaP
CMHA
CDDP / mL MilliQ water to make a suspension that was 
injectable through a 25 gauge needle.  All solutions/liquids during the synthesis process were 
sterile-filtered with a 0.2 μm filter.  The nCaPCMHACDDP suspension was stored at room 
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temperature and shielded from light. nCaP
D
CDDP was made as previously described except 
Calcium Lactate pentahydrate was used instead of Ca(NO3)2·4H2O), to match the calcium used 
in nCaP
CMHA
CDDP.   
The concentration of CDDP was determined by inductively coupled plasma-optical 
emission spectroscopy (ICP-OES) (Perkin Elmer® Optima™ 5300 DV, ESIS Inc., Cromwell, 
CT) on nCAPCDDP samples of known volume dissolved in 1N HCl. Particle size analysis 
(PSA) was performed via dynamic light scattering using a 90 Plus Particle Sizer (Brookhaven 
Instruments, NY). Samples were prepared by sonicating the particle suspension and diluting the 
suspension 12x in MilliQ ® water.  The morphology and size of the particles were observed by 
using a Hitachi H-7650 transmission electron microscope (TEM). TEM samples were prepared 
by sonicating the particle suspension and diluting the suspension 26x in MilliQ water then 10x in 
70% ethanol. A 5 uL sample was placed on a formvar carbon coated 300 mesh Cu grid. Sample 
sat for 1min and then any excess solution was removed using filter paper. Prior to imaging the 
sample completely dried in air for 5 min.  Samples were imaged at 80 kV with the TEM.  X-ray 
diffraction (XRD) was used to determine changes in crystallinity with addition of stabilizer and 
to compare dry vs wet nCaP. Samples of lyophilized calcium phosphate without stabilizer 
(microCaP), lyophilized nCaP
CMHA 
or nCaP
D
 and wet nCaP
CMHA 
and nCaP
D
 were analyzed using 
a Bruker D2 Phaser. 
4.2.3 nCaP
CMHA
CDDP and nCaP
D
CDDP In Vitro Drug Release 
In vitro drug release studies were performed using a USP apparatus 4 (Sotax CE, Sotax, 
Horsham, PA) modified with a dialysis adapter with a molecular weight cut off of 100 kD.  A 
sample of 0.4 mL of particle suspension was loaded into the dialysis adapter with 100 uL release 
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medium. Release medium was 10 mM PBS pH 7.4 with 0.1% sodium azide. A flow rate of 8 
mL/min was used for the study with the cell temperature maintained at 37ºC. Release samples 
were drawn at 1h, 3h, 5h, 7 hr, 12 hr, 1d, 2d, 3d, 4d, 5d, 6d, 7d and 10d.  At each time point 5 
mL of release solution was taken and replaced with 5 mL of fresh PBS.  CDDP content in the 
release solution was determined by ICP-OES.  Media replacement during the release study was 
considered in the calculation of cumulative release.  
Another type of release study was conducted to obtain CDDP released from 
nCaP
CMHA
CDDP (drug loading 139 ug CDDP/ mg nCaP
CMHA
) and nCaP
D
CDDP (drug loading 
216 ug CDDP/ mg nCaP
D
) specifically for use in cytotoxicity studies.  In these release studies 
100 uL of the nCaPxCDDP suspensions were loaded into triplicate Eppendorf tubes with 1.2 mL 
sterile 0.9% saline. Samples were sonicated then placed on a heated rocker at 37ºC for 3 days, 
where mixing was conducted by tumbling the tube contents.  The samples were centrifuged 
14000 rpm in an Eppendorf Micro Centrifuge with a 5415 C rotor (Hamburg, Germany).  The 
entire supernatant was collected and filtered using a 0.2 µm filter. The three samples of 
nCaPxCDDP supernatant were pooled and CDDP content was measured by ICP-OES.   
4.2.4 Surface Plasmon Resonance 
Interaction of nCaP
CMHA
CDDP, CMHA (~34 kDa) and HA (60 kDa) with CD44 were studied 
with surface plasmon resonance, BioRad ProteOn™ XPR36 with a GLC ProteOn™ sensor chip 
(BioRad, Hercules, CA). Recombinant human CD44-Fc chimera (~170 kDa) (R&D Systems, 
Minneapolis, MN) was immobilized on the sensor chip using amine coupling chemistry ProteOn 
Amine Coupling Kit. Briefly, the sensor chip surface was activated with 1:1 mixture of sulfo-N-
hydroxysuccinimide (sulfo-NHS) and ethyl-3(3-dimethylamino)propyl carbodiimide (EDC) for 7 
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min. CD44-Fc was dissolved in 10mM acetate buffer pH 4 to a concentration of 5 ug/mL and 
flown over the activated surface for 14 min. The remaining reactive groups were blocked with 
1M ethanolamine HCl pH 8.5. A blank flow channel (FC) was prepared by EDC/NHS activation 
without the CD44 receptor. Throughout all the SPR measurements PBS pH 7.4 supplemented 
with 0.005% Tween 20 was used as the running buffer. Samples were diluted with running 
buffer. CMHA and HA were diluted to concentrations of 1 uM and 5 uM. .  nCaPxCDDP 
samples were diluted to a concentration of 350 ug/ml, which was found to be a good compromise 
between sufficient binding response and bulk refractive index shift.  The samples were injected 
over the sensor chip surface coated with human CD44-Fc at 100 uL/min for 150 s. The 
dissociation in the running buffer took place for another 600 s. Between the measurement cycles 
the sensor chip surface was regenerated with 10mM glycine HCl pH 2.0 at a flow rate of 200 
uL/min. The responses on the blank flow cell were subtracted from the CD44-Fc coated flow 
cell.  
4.2.5 Flow Cytometry 
LMS, BT-474 and BT-474m cells were analyzed for CD44 and CD24 expression using flow 
cytometry. NIH-373 cells were analyzed for CD44 expression alone.  Cells were washed once 
with phosphate-buffered saline (PBS) and then harvested with 0.05% trypsin/0.025% EDTA. 
Detached cells were washed with PBS that is supplemented with 0.2% (w/v) bovine serum 
albumin (BSA) (wash buffer), and resuspended in the wash buffer (10
6
 cells/100 uL). 
Combinations of fluorochrome-conjugated monoclonal antibodies obtained from BioLegend® 
(San Diego, CA) reactive against human and mouse CD44 (Alexa Fluor® 647) and BD 
Pharmingen™ (San Jose, CA) CD24 (PE-Cy7) or their respective isotype controls were added to 
the cell suspension at concentrations recommended by the manufacturer and incubated at 4°C in 
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the dark for 30 to 40 min. The labeled cells were washed in the wash buffer, then analyzed on a 
MACSQuant® Analyzer, MACS Miltenyi Biotec (Auburn, CA).  
4.2.6 Cellular Uptake Studies 
nCaP
CMHA-AF488
 was made via the method described in 4.2.2, with minor modifications. Briefly, 
Alexa Fluor® 488 labeled CMHA was incorporated into the CMHA solution at 6% the total 
volume of CMHA used in the precipitation.  Otherwise all reaction steps to create nCaP
CMHA
 
were performed the same.  BT-474m cells were seeded at a density of 1 x 10
5
 cells in an 8-well 
glass bottom plate and allowed to adhere for 24 hours.  After which nCaP
CMHA-AF488
 was added at 
the following concentrations: 200 ug/mL, 1 mg/mL, or 2 mg/mL in 500 uL complete media.  
After 2, 8, and 18 h post-incubation, the glass slide chambers were washed 2x with PBS to 
remove any loose nanoparticles, and the cells were fixed 4% paraformaldehyde in PBS for 15 
min. The fixed cells were washed with PBS 3x to remove the excess paraformaldehyde, and then 
dried for 3 h. The fixed cells were stained and mounted with Prolong® Gold anti-fade mounting 
media containing the nuclear stain 4′,6-diamidino-2-phenylindole (DAPI) (Thermo Fisher 
Scientific, Waltham, MA). Microscopic analysis was performed using a Nikon A1R Spectral 
Confocal Microscope. Conditions of the confocal microscopic analysis were a Z-stack thickness 
of 11 um, individual stack thickness of 0.35 um and an oil immersed 40x objective. 
4.2.7 Cytotoxicity  
Cytotoxicity experiments were conducted using NIH-3T3, LMS, BT-474 and BT-474m cells 
plated in 96 well plates. at 4 x 10
4
, 5 x 10
4
, 6 x 10
4
, and 2 x 10
5
 cells/mL, respectively with 50 uL 
suspension per well. NIH-3T3 and BT-474 cells were negative control cell types relative to 
CD44 expression, as both cell types have CD44 negative or low expression.  LMS and BT-474m 
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cells were experimental cells for CD44 targeted cytotoxicity.  These cell types allow for the 
determination of cytotoxicity of nCaP
CMHA
CDDP relative to CD44 expression to elucidate if 
CMHA enhances cell uptake and consequently cytotoxicity.  Cells were allowed to proliferate 
for 24 hours following which drug was added in 50 uL volumes. The following groups were 
examined: CDDP, Aq-CDDP, CMHA reacted with Aq CDDP (Aq CDDP – CMHA), D reacted 
with Aq CDDP (Aq CDDP – D), CDDP released from nCaPCMHACDDP, CDDP released from 
nCaP
D
CDDP, nCaP
CMHA
CDDP, nCaP
D
CDDP, nCaP
CMHA
, nCaP
D
, CMHA and D.  Each group 
was serially diluted 1:3 across the plate using PBS. Cells were assayed 48 h after drug addition 
using in an MTS assay (CellTiter 96® AQueous One, G3580, Promega Corp., Madison, WI), 
where metabolic activity was determined using a Spectramax Plus
384 
Spectrophotometer 
(Molecular Biosciences, Sunnyvale, CA) at an absorbance of 490nm. To determine the IC50 
(50% inhibitory concentration) a non-linear regression curve fit analysis was performed with at 
least four replicates per group per concentration.  All experiments shown were repeated at least 
twice and often thrice.   
4.2.8 BT-474m Tumor Take Rate 
To assess the growth parameters of BT-474m tumors a tumor take rate study was performed. 
This was performed to ensure that tumors will growth at a steady pace, without growing too fast 
causing necrosis or too slow such that they regress on their own. We utilized a BD Matrigel™ to 
cells in base media ratio of 60:40. Four mice were used per group.  The tumor take rate study 
was conducted using 8, 6-8 week old, athymic nude mice.  5 x 10
5 
cells in a 100 uL volume were 
injected subcutaneously, based on the cell number utilized for a comparable transformed breast 
cancer cell type
50
.  Animals were monitored at least every other day for normal grooming and 
appearance. Tumors were measured beginning at day 7 following inoculation.  At this time, the 
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Matrigel has degraded from the initial 100 uL injection, allowing for a true cell-based tumor 
volume measurement.  
 4.2.9 nCaP
CMHA
CDDP In Vivo Maximum Tolerable Dose Determination 
Two J:Nu mice carrying BT-474m tumors were injected once intratumorally with 10 mg/kg 
nCaP
CMHA
CDDP (80-90 uL per injection). A second study was conducted using athymic nude 
mice, where a 7 mg/kg dose of nCaP
CMHA
CDDP (60-70 uL) was administered once 
intratumorally.  For both studies animals were monitored daily for weight loss and grooming.   
4.2.10 nCaP
CMHA
CDDP In Vivo Anti-Tumor Efficacy and Toxicity Study 
An efficacy and toxicity study was performed using BT-474m cells in J:Nu mice. The study 
included 24, 6 week old mice inoculated with 5x10
5
 BT-474m cells in 100μL of a 60 : 40 ratio of 
BD Matrigel™ : cells in base media in the right rear flank via a 25-gauge needle.  Tumors were 
measured daily 7 days following inoculation using digital calipers to calculate the tumor volume 
as follows:  V = (W)
2
 * L * 0.4   
Tumors were treated once with: 2.8 mg/kg (60 uL) CDDP NT (8 mice), 60 uL of saline NT (4 
mice), 60 µL of nCaP
CMHA
 NT (4 mice), 7 mg/kg nCaP
CMHA
CDDP NT (8 mice), when tumor 
volume reached 100 ± 10 mm
3
.   
Systemic toxicity was evaluated by weight change and overall grooming/appearance.  
Tumor volume and mouse weight were monitored at least every other day. Mice were euthanized 
due to significant weight loss (> 15%), a tumor length measurement greater than 20 mm, or 
completion of the study (day 30).  All animal experimental procedures were approved by the 
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Animal Care and Use Committee of the University of Connecticut Health Center, (Farmington, 
CT). 
4.2.11 Statistical Analysis  
Statistical analysis was performed using an unpaired t-test (comparing two groups) or Tukey 
one-way ANOVA (comparing three or more test groups to a control group), as indicated in the 
methods.  A P-value of less than 0.05 was considered statistically significant.  Data is presented 
as a mean value with its standard deviation indicated (mean + SD).   
4.3 Results 
4.3.1 Physical Characterization of nCaP
CMHA
CDDP 
A side by side comparison of nCaP
CMHA
CDDP and nCaP
D
CDDP is shown in Table 4.1.  
Nanoparticle yield is of great importance for scale up
123
. Precipitation of nCaP
CMHA 
results in a 
7x the yield of nCaP
D
.  The average CDDP concentration in suspension is higher for 
nCaP
D
CDDP, as is the drug loading.  nCaP
CMHA
CDDP are statistically larger than nCaP
D
CDDP, 
but their polydispersities are comparable. Transmission electron microscopy (TEM) (Figure 4.2) 
showed that nCaP
CMHA
CDDP and nCaP
D
CDDP in suspension form small aggregates that 
correlate well with their measured particle size using DLS, 204 ± 13 nm and 149 ± 7 nm, 
respectively.  Zeta potentials of nCaP
CMHA
CDDP and nCaP
D
CDDP were -43±4 mV and -35±5 
mV, respectively.  A zeta potential of ± 30 mV has enhanced stability as the surface change aids 
in preventing aggregation
74
.  XRD comparing the nCaPs
 
as a wet suspension, nCaP
 
lyophilized 
and microCaP showed that both nCaPs are poorly crystalline with the major peak occurring at 
30º corresponding well with hydroxyapatite (HA) while microCaP was more crystalline in nature 
resembling brushite and poorly crystalline HA (Figure 4.3) 
113,135
. 
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4.3.2 nCaP
CMHA
CDDP In Vitro Release 
The in vitro release of the nCaP
CMHA
CDDP and nCaP
D
CDDP in PBS, pH 7.4, at 37° C over time 
can be seen in Figure 4.4.  Both formulations exhibit continuous in vitro release. A burst release 
of CDDP was exhibited in the first 2 days, with slower, continuous release out to day 10.  At day 
2, nCaP
CMHA
CDDP released 74% of the total CDDP available while nCaP
D
CDDP released 45%.  
At the 7 day completion of the release study nCaP
CMHA
CDDP released 86% of bound CDDP and 
nCaP
D
CDDP released 74.5%.  Drug was released significantly faster and more completely from 
nCaP
CMHA
CDDP than from nCaP
D
CDDP.   
In the three day release study conducted to obtain a concentrated supernatant to assess if active 
drug was released via cytotoxicity testing, nCaP
CMHA
CDDP released 89% of the total CDDP 
loaded. nCaP
D
CDDP released only 34% of the total CDDP available for release.  Both 
supernatants containing released drug were stored and used for direct comparison to the same 
batch of intact nCaP
CMHA
CDDP and nCaP
D
CDDP in cytotoxicity studies. 
4.3.3 Surface Plasmon Resonance 
To assess the interaction and binding of CMHA and nCaP
CMHA
CDDP to CD44, SPR was 
performed.  Human CD44 chimera was immobilized on the sensor chip to determine the binding 
of HA, CMHA, nCaP
CMHA
CDDP.  To correct for bulk shift due to size of the nanoparticles, 
nCaP
D
CDDP was examined as a control. As expected the HA most effectively bound CD44 with 
CMHA nearing the binding affinity of HA but not matching it (Figure 4.5).  nCaP
CMHA
CDDP 
also binds CD44, but this binding is lower than free CMHA or HA. Importantly, this binding is 
specific as it overcomes any bulk interactions observed with nCaP
D
CDDP. 
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4.3.4 Flow Cytometry 
Flow cytometry analysis of NIH-3T3 cells revealed that they minimally express CD44, at 8.94% 
of the population after isotype control subtraction (Figure 4.6).  We did not examine these cells 
for CD24, as they are mouse fibroblasts and their expression of CD24 is not important for this 
study.  LMS cells which are transformed human mammary cancer cells, were analyzed for CD24 
and CD44 expression, finding they stained 97.3% positive for CD44 and negative for CD24 
(Figure 4.7 C). Importantly, this phenotype is associated with the breast CSC phenotype
52
.  BT-
474 stained 1.71% positive for both CD44 and CD24, but the majority of cells stained positively 
for CD24 alone, 98.3% (Figure 4.8 C)  BT-474m cells stained 99.7% positive for CD44 and 
negative for CD24, comparable to profile of the LMS cells, CD44
+
/CD24
-/low
. 
4.3.5 Cellular Uptake Studies
 
In this cell uptake experiment, BT-474m cells were used as they have high CD44 expression.  
Cells were administered varying doses of nCaP
CMHA-AF488 
at
 
200 ug/mL, 1 mg/mL, or 2 mg/mL.  
Cells were imaged at 2, 8, and 18 h of incubation following washing to remove any free 
nanoparticles.  No significant uptake was found for the 200 ug/mL or 1 mg/mL concentrations at 
any time tested (images not shown).  At the 2 mg/mL dose, significant cellular uptake was found 
at 18 hours post treatment. These results are shown in Figure 4.9 A-D.  Z-stack images were 
obtained, confirming the nCaP
CMHA-AF488 
was within the cell with nuclei counterstained with 
DAPI.  
4.3.6 Cytotoxicity Evaluation of nCaP
CMHA
CDDP and nCaP
D
CDDP 
NIH-3T3 (CD44
low
) and LMS (CD44
+
/CD24
-
) cells were used to study the cytotoxicity of: 
CDDP, Aq-CDDP, CMHA reacted with Aq CDDP (Aq CDDP – CMHA), D reacted with Aq 
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CDDP (Aq CDDP – D), CDDP released from nCaPCMHACDDP (nCaPCMHACDDP (R)), CDDP 
released from nCaP
D
CDDP (nCaP
D
CDDP (R)), nCaP
CMHA
CDDP, nCaP
D
CDDP, CMHA and D.  
CMHA is not cytotoxic (Figure 4.9 A). Darvan alone caused some toxicity at a top dose of 1 
mg/mL (Figure 4.9 B). Non-linear regression curve fit analysis was performed for each of these 
treatments and the resulting IC50 values are shown in Figure 4.9 C.  Both CDDP released from 
nCaP
CMHA
CDDP and nCaP
D
CDDP have comparable cytotoxicity to CDDP alone. D reacted with 
Aq CDDP inhibits the cytotoxicity of Aq CDDP, this interaction also inhibits the cytotoxicity of 
nCaP
D
CDDP (P < 0.05). 
LMS cells were analyzed against the same groups as the NIH-3T3 cells.  CMHA has no 
cytotoxicity to LMS cells (Figure 4.10 A).  D has some cytotoxicity at the top dose administered, 
1 mg/mL (Figure 4.10 B). The calculated IC50 values are shown in Figure 4.10 C.  CDDP 
released from nCaP
CMHA
CDDP has comparable cytotoxicity to CDDP.  Both nanoparticle 
formulations were significantly less cytotoxic than CDDP (P < 0.05).  
BT-474 (CD44
-/low
/CD24
+
) and BT-474m (CD44
+
/CD24
-/low
) cells were examined in 
cytotoxicity tests against: CDDP, Aq-CDDP, CMHA reacted with Aq CDDP (Aq CDDP – 
CMHA), D reacted with Aq CDDP (Aq CDDP – D), nCaPCMHACDDP and nCaPDCDDP.  The 
calculated IC50 values for each group with BT-474 cells are shown in Figure 4.11 A. Overall, a 
similar trend was found against BT-474 cells as those previously tested with one important 
exception; nCaP
CMHA
CDDP was significantly more cytotoxic than CDDP against BT-474 cells(P 
< 0.05).  Against BT-474m cells the calculated IC50 values are shown in Figure 4.11 B. 
Importantly, nCaP
CMHA
CDDP was as cytotoxic as free CDDP. nCaP
D
CDDP and D reacted with 
Aq CDDP were significantly less cytotoxic than CDDP (P < 0.05).  
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Upon a routine mycoplasma test, it was determined that our BT-474 and BT-474m cells 
were positive for mycoplasma (MycoAlert™ Mycoplasma Detection Kit, Lonza Group Ltd., 
Basel, Switzerland).  Mycoplasma is a very common cell culture contamination that affects 
laboratories worldwide. It is estimated that ATCC, National Cancer Institute and the FDA have 
an average mycoplasma contamination rate in cell culture of 13.5%
151
.  This rate is expected to 
be higher at academic institutions, due to a lack of testing for mycoplasma and reliance of 
antibiotics.  In cell culture a mycoplasma can outnumber the cells by 1000:1, competing for 
nutrients causing changes in cell growth and protein production
152
.  Due to this, a commercial 
mycoplasma removal kit was purchased and used on the BT-474 and BT-474m cells 
(MycoZap™ Elimination Reagent, Lonza). After treatment both cell types tested negative for 
mycoplasma and thus all of the studies were repeated using mycoplasma free cells.  
Flow cytometry was repeated on the BT-474m cells after mycoplasma removal to ensure 
their expression of CD44 remained high. The CD44
+
/CD24
-/low 
phenotype remained after 
mycoplasma removal, Figure 4.12 C.  BT-474 cells normally have a CD44
-/low
/CD24
+
 therefore it 
expected that their phenotype would change in the presence of mycoplasma
51,153
.  All of the 
cytotoxicity tests performed prior to mycoplasma testing were repeated three times following 
mycoplasma removal. Data shown represents one test, but the trend remains the same from 
experiment to experiment.  The cytotoxicity of each stabilizer and the resulting nanoparticles 
were examined against BT-474 and BT-474m cells (Figure 4.13 A-D).  CMHA does not have 
any inherent toxicity to either cell type (Figure 4.13 A). Darvan caused 50% cell death at its top 
concentration of 1 mg/mL. with BT-474m cells (Figure 4.13 B).  Neither nanoparticle 
formulations were cytotoxic at concentrations tested which match the nCaP in nCaPxCDDP test 
groups (Figure 4.13 C & D).  
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The cytotoxicity of CDDP, Aq CDDP, Aq CDDP reacted with CMHA (Aq CDDP – 
CMHA), Aq CDDP reacted with D (Aq CDDP – D), nCaPCMHACDDP and nCaPDCDDP were 
re-examined against BT-474 and BT-474m cells. The curve fits are shown in Figure 4.14 A-F for 
BT-474 cells.  The IC50 values calculated from these curve fits are shown in Figure 4.15.  
nCaP
CMHA
CDDP remained significantly more cytotoxic than CDDP alone, as did Aq CDDP (P < 
0.0001). Additionally, nCaP
D
CDDP was the most cytotoxic, which was not found in experiments 
with cells infected with mycoplasma.  The curve fits for each group tested against BT-474m cells 
are shown in Figure 4.16 A-F.  The IC50 values calculated from these curves are shown in 
Figure 4.17.  Here there were no significant differences between groups tested compared to 
CDDP, with the exception of Aq CDDP – D, which was very significantly less cytotoxic (P < 
0.0001).  
4.3.7 BT-474m Tumor Take Rate  
Two tumor take rate studies were conducted with BT-474m cells. Athymic nude mice were 
injected with 5 x 10
5 
BT-474m cells per injection in 100 uL of BD Matrigel™ :cells in base 
media at a ratio of 60:40 subcutaneously.  Seven days following cell inoculation, tumors were 
palpable and the Matrigel plug had visibly degraded from the time of injection.  At this time 
tumors were quite small, 50 mm
3 
on average. After approximately 12 days tumors were 100 mm
3
 
on average (Figure 4.18 A).  Animals were monitored for 25 days following inoculation where 
tumors continued to grow steadily up to 500 mm
3 
without necrosis.  
4.3.8 nCaP
CMHA
CDDP Maximum Tolerable Dose 
A maximum tolerable dose study was conducted first in two 6-8 week old, J:Nu mice bearing 
BT-474m tumors at 150 mm
3
, where each animal received nCaP
CMHA
CDDP at 10 mg/kg (80-90 
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uL) intratumorally.  Four days following treatment one mouse lost more than 15% of its weight 
at the time of treatment.  The other mouse lost only 6.7% of its weight at treatment and fully 
recovered.  The second MTD study was conducted using 6-8 week old, athymic nude mice 
bearing BT-474m tumors. Animals were treated at an average tumor volume of 170 mm
3
, 14 
days following cell inoculation.  Four animals were treated with 7 mg/kg nCaP
CMHA
CDDP (60-
70 uL) intratumorally.  Four additional animals were monitored as untreated controls. The results 
are shown in Figure 4.18 B, where a maximum weight loss was 5%, two to five days following 
treatment. This is an acceptable weight loss during treatment with chemotherapeutics, therefore 
this dose was deemed tolerable. 
4.3.9 In Vivo Anti-Tumor Efficacy and Toxicity Study 
The in vivo anti-tumor efficacy of the nCaP
CMHA
CDDP was evaluated using BT-474m human 
xenograft tumors in 6 week old J:Nu mice.  Mice were injected with 5x10
5 
BT-474m cells in 100 
µL of 60% Matrigel™ 60% cells in base media subcutaneously. Tumors were treated once with: 
2.8 mg/kg (60 uL) CDDP NT (8 mice), 60 uL of saline NT (4 mice), 60 µL of nCaP
CMHA
 NT (4 
mice), 7 mg/kg nCaP
CMHA
CDDP NT (8 mice), when tumor volume reached 100 ± 10 mm
3
.  The 
change in tumor volume and mouse weight was evaluated for 30 days post treatment (Figure 
4.19). No animal experience weight loss greater than 2% (data not shown). Near tumor delivery 
of 2.8 mg/kg CDDP was most effective at inhibiting tumor growth.  No treatment caused toxicity 
to the animals as measured by weight loss and overall grooming/appearance.  Survival over time 
post treatment was evaluated for each group. The results are shown in Figure 4.20.  
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4.4 Discussion 
The addition of CMHA during precipitation of CaP resulted in successful stabilization of nCaP. 
TEM images reveal small 30-80 nm particles, agglomerated into larger particles, which likely 
accounts for the 200 nm size measured by DLS.  The introduction of D or CMHA clearly 
restricts the crystallization of CaP, as can be seen by the broad peaks of nCaP XRD spectra. 
MicroCaP created by precipitation without the addition of stabilizer exhibits a crystalline pattern 
with major peaks comparable to brushite, (calcium hydrogen phosphate dehydrate, CaHPO4· 
2H2O). This form of calcium phosphate naturally occurs and dissolves in the body as kidney 
stones and is therefore highly biocompatible
135
.  The particle sizes obtained here made for a 
readily injectable nanoparticle suspension via a 25G needle. 
It was shown in previous studies and Chapter 2,  that D halts CaP crystal growth
16
.  This 
is believed to be due in part to the repeating carboxylate groups throughout the polymer.  There 
is significant literature showing  the carboxylate groups of sodium citrate (3 carboxylate groups 
per molecule) interact with the Ca ions during CaP precipitation acting as a surfactant to halt 
nucleation
134,154–157
.  The interaction of D and CaP created regularly shaped nCaP, with low 
polydispersity.  This was also true for citrate.  Unfortunately, these stabilizers inhibited the 
cytotoxicity of CDDP. Interestingly, it was recently shown that citrate nearly irreversibly binds 
CDDP and renders it unable to intercalate with DNA, making it biologically inactive
158
. This 
finding complements our findings in Chapter 3.  Thus, a balance needs to be achieved between 
stable nCaP and their effective binding and release of biologically active CDDP. The findings of 
Chapters 2 & 3 led us to the utilization of a stabilizer that has biological targeting capability 
concurrent with nCaP stabilization.  Here the approach was to use CMHA to enhance uptake of 
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nCaP
CMHA
CDDP by cells expressing CD44.  CMHA is HA with additional carboxylate groups, 
but in comparison to D and citrate there are fewer carboxylate groups per molecular weight. 
To date, there is not a compendial in vitro release test for parenteral dosage forms.  The 
current USP apparatus are specified to test release/dissolution of oral and transdermal dosage 
forms.  As the development of liposomes and nanoparticles advances towards a commercial 
product, there is a desperate need to evaluate batch to batch quality by developing an in vitro 
release method that can discriminate between small variations in formulation.  Published in vitro 
release testing methods for controlled release nanoparticles/liposomes include, flow through
22
, 
dialysis sac
119,124,159
, or sample and separate
15,16
. Major drawbacks exist for sample and separate 
as well as dialysis sac methods.  Sample and separate methods involve the use of centrifugation 
and/or filtration where the liposomes can be disrupted causing erroneous release, additionally 
great variability exists from lab to lab with vessel size, agitation and centrifugation making the 
test not reproducible.  Dialysis methods are limited by insufficient agitation within the dialysis 
sac, delayed diffusion of released drug through the dialysis membrane and high concentration of 
carrier within the sac limiting release
120,121
.  Dr. Diane Burgess’ lab at the University of 
Connecticut, has been working towards the development of a compendial release testing 
method/system to fill the current void for nanoparticle formulations.  They developed a dialysis 
adapter to fit within the standard sample cell in the Sotax™ CE7 USP apparatus 4, where the 
dialysis membrane MWCO is chosen such that when the drug of interest releases, it can freely 
flow through the dialysis membrane and the carrier (liposome or nanoparticle) stays within the 
dialysis adapter
22
.  They were able to discriminate between different liposomal formulations 
using the dialysis adapter modified USP 4 apparatus.  Here we compared the in vitro release of 
CDDP from nCaP
CMHA
CDDP and nCaP
D
CDDP.  In a side-by-side release test, nCaP
CMHA
CDDP 
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released 73% of the CDDP bound compared to 45% from nCaP
D
CDDP in 2 days.  As release 
continued, nCaP
CMHA
CDDP released a total of 86% while nCaP
D
CDDP released 74.5%.  Several 
papers have published the use of HA to create particles containing CDDP via ion complexes 
between the carboxylate groups of HA to aquated species of CDDP
160–162
.  In each study it was 
shown that Aq CDDP that had been complexed with HA could subsequently be released both in 
vitro and in vivo.  Release was enhanced in the presence of Cl
-
 ions
160
.  This taken together with 
the cytotoxicity examinations of each stabilizer reacted with Aq CDDP may explain the 
enhanced release of CDDP from nCaP
CMHA
CDDP over nCaP
D
CDDP, where the interaction 
between Aq CDDP and CMHA is weaker than with D.   
SPR analysis of targeted nanoparticles is challenging.  SPR systems utilize expensive 
microfluidics that normally transport solutions containing ligands or proteins of interest, but 
generally not solid materials such as nCaP particles.  Of additional concern is the ability to 
correct for bulk response due to the relatively large nanoparticles passing over the sensor.  Here 
we were able to use nCaP
D
CDDP as a comparably sized, non-specific nanoparticle control.  The 
density of receptor (here CD44) immobilized on the chip is inherently related to the response 
measured, therefore we utilized a low density of CD44 on the chip surface
163
.  After correcting 
for bulk nanoparticle response, it is clear that nCaP
CMHA
CDDP does effectively bind CD44.  The 
highest binding observed was for HA (60 kDa), followed by CMHA (34 kDa) alone. The 
chemical modification of HA to create CMHA occurs at 15 – 20% of the repeating 6’-OH groups 
of the N-acetylglucosamine residues.  The interaction of CD44 and HA has low affinity but high 
avidity.  A single HA disaccharide contains an N-acetyl-D-glucosamine and D-glucuronic acid, 
HA2. It has been shown that HA6 is necessary for binding CD44, but HA10 is more preferential
164
.  
Additionally, divalent binding occurs with HA20 and larger oligomers.  This likely explains the 
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slight reduction in binding of CMHA to CD44, due to an interruption of sugar residues by the 
added carboxylate groups of CMHA compared to HA.  This may also explain the significant 
time required for cellular uptake of nCaP
CMHA-AF488
, where uptake was only found significantly 
at 18 hours post treatment.  This was a preliminary test of cellular uptake.  These were 
insufficient to prove that nCaP
CMHA-AF488 
cellular uptake was mediated by CD44.  To do so, at 
least two controls are necessary, a CD44- cell type and a CD44+ cell type pre-treated with HA to 
effectively saturate the CD44 receptors.  nCaP
CMHA
CDDP showed lower binding than CMHA, 
which is believed to be due to two factors.  By utilizing fluorescently labeled CMHA, we were 
able to determine that during precipitation of nCaP
CMHA
 only 30% of the available CMHA is 
incorporated. Additionally, nCaP
CMHA
CDDP is stored as a suspension which allows the CaP to 
undergo Ostwald ripening which could further trap the CMHA within the nCaP core
93,165
.  
Interestingly, nCaP
CMHA
CDDP did not show preferential toxicity to cells with high CD44 
expression (LMS and BT-474m) compared to those with low or negative CD44 expression 
(NIH-3T3 and BT-474).  It was hypothesized that the CMHA would allow for preferential 
cytotoxicity to cells with high CD44 expression due to the targeting of CD44 via CMHA.  It was 
expected that the BT-474m and LMS cells would be chemotherapy resistant, as it was shown that 
LMS cells were resistant to other chemotherapies (docetaxel and tamoxifen) 
17,50
.  When treated 
with CDDP alone, both BT-474m and LMS cells were relatively sensitive to CDDP.  This is 
likely explained by the nature of CDDP toxicity, where it intercalates with DNA, causing DNA 
adducts that cannot be removed by DNA repair machinery prior to replication resulting in cell 
death. LMS and BT-474m cells divide at 2-3x the rate of their non-transformed counter-parts, 
MCF-7 and BT-474 cells, respectively.  Importantly, nCaP
CMHA
CDDP was as cytotoxic as 
CDDP alone against all cell types tested.  This finding is not common for targeted nanoparticles 
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utilizing HA and may be due in part to released CDDP from the formulation.  The controlled 
release of CDDP from nCaP
CMHA
CDDP allowed for prolonged delivery of drug to the slower 
replicating BT-474 cells, which could explain the enhanced cytotoxicity of nCaP
CMHA
CDDP 
over CDDP alone.  HA bioconjugates with Taxol were less cytotoxic than free Taxol against 
cells expressing CD44 and had limited to no cytotoxicity against cells that did not express 
CD44
166,167
.  Mesoporous silica nanoparticles targeted with HA carrying doxorubicin, were 
significantly more cytotoxic than doxorubicin alone against CD44 expressing cells, but were 
significantly less cytotoxic to CD44 negative cells
168
.  This can be explained by specific CD44 
mediated uptake that allowed drug to release intracellularly, where cells lacking CD44 did not 
take up the particles.  nCaP
CMHA
CDDP may not be as readily taken up as nanoparticles with HA 
on their surface, due to limited CMHA on the surface and the chemical modifications on HA to 
make CMHA.  
This study was the first to create BT-474m cell based tumors in nude mice.  BT-474m 
cells were developed following a previously reported method for transformation of human 
epithelial breast cancer cells, in the same lab at UCHC
50
.  Within that research an animal model 
was developed, where 5 x 10
5 
cells were injected orthotopically into athymic nude mice using 
Matrigel, where tumor volume reached 600 mm
3
, 20 days following inoculation.  Here, we also 
used 5 x 10
5
 cells, but cells were injected subcutaneously in the flank of J:Nu mice.  The BT-
474m tumors created here showed high variability in tumor volume in the control groups as well 
as the treated groups.  Due to the high variability in tumor volume, significant differences did not 
exist between treatment groups.  From our experience with the FaDu tumor model in Chapter 3 
of this dissertation, we found that 2 x 10
5 
and 8 x 10
5 
FaDu cells were insufficient for significant 
tumor growth beyond inoculation volume and 2 x 10
6 
was sufficient with limited differences in 
Jessica Lea Woodman – University of Connecticut, 2014 
 
104 
 
tumor volume from the 5 x 10
6 
cell number inoculation.  If we injected a higher number of BT-
474m cells we may have found limited variability in tumor volume, because sufficient cells were 
injected such that all tumors grew beyond their inoculation volume.  
Levy-Nissenbaum et al. recently showed that a local dose of polymer carrying CDDP 
administered near or surrounding the tumor significantly increased the anti-tumor efficacy 
compared to an intratumoral injection
169
. Tumor tissue is very dense with high interstitial fluid 
pressure
82
 and therefore we have had difficulty administering even very small (60 uL) volumes 
directly into the tumor. These complications taken together with the results of Levy-Nissenbaum 
led us to change to a near tumor administration of treatment.  To do so, the skin above each 
tumor was gently lifted away from the tumor surface and with a single injection drug was 
deposited on either side of the tumor.  For some animals this was easy to achieve and others, this 
proved more difficult as the skin would not lift from the tumor surface.  As this was our first 
attempt at near tumor treatment, we are unsure if this complication has any impact on the 
standard deviations within each treatment group.  At the time of resection, depots of 
nCaP
CMHA
CDDP were found.  Animals with the largest tumor volumes had nCaP
CMHA
CDDP 
located on just one side of the tumor, while animals with smaller tumor volumes had depots on 
opposing sides of the tumor.  We believe the lack of even distribution nCaP
CMHA
CDDP may 
have contributed to lack of anti-tumor efficacy observed in these animals.  nCaP
CMHA
CDDP does 
not freely diffuse throughout the tumor due to the density of the tumor and therefore only the 
areas of the tumor proximal to the nCaP
CMHA
CDDP depot are treated with CDDP.  The overall 
goal of this treatment modality is to cover more of the tumor area with drug, therefore if the drug 
deposited on just one side of the tumor, potentially fewer cancer cells we treated.  Taken together 
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it is likely that, the ability of free CDDP to diffuse throughout the tumor enabled the tumor 
growth inhibition observed in the CDDP alone group.  
4.5 Conclusions 
CMHA is a novel and effective stabilizer for nCaP that can bind CD44 for potential targeting 
applications.  Importantly, we determined that CMHA has no negative impact of the biological 
activity of CDDP in vitro, against human breast cancer cells.  nCaP
CMHA
CDDP allowed for 
efficient release of CDDP in neutral PBS which should be enhanced by CaP dissolution in lower 
pH environments, like that found in solid tumors.  nCaP
CMHA
CDDP had equivalent cytotoxicity 
to CDDP alone against both CD44
+ 
and CD44
- 
cells. Tumors are very heterogeneous in cell 
surface expression and therefore non-exclusive cytotoxicity is important in vivo.  Our in vivo 
efficacy study showed that near tumor delivery of 2.8 mg/kg CDDP was most effective at 
inhibiting tumor growth.  This finding agrees with a recently published clinical trial showing 
neoadjuvant CDDP treatment was effective for patients with TNBC, though this treatment has 
not yet been adopted clinically. Here we locally administered less than a third of the typical 
systemic dose of CDDP for a mouse and found excellent tumor growth delay.  Importantly, a 
higher dose of nCaP
CMHA
CDDP should be examined in vivo to evaluate the targeting of therapy 
resistant CD44+ cells, which should increase the efficacy of locally delivered CDDP.  
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Figure 4.1 Chemical modification of hyaluronic acid (HA) to synthesize carboxymethyl 
hyaluronic acid (CMHA). 
 
Table 4.1 Side by side comparison of nCaP
CMHA
CDDP and nCaP
D
CDDP batch characteristics. 
Ratio of components, precipitation volume, and stabilizer final concentration remain the same 
from batch to batch. Yield, CDDP concentration, drug loading, particle size and polydispersity 
represent averages and standard deviations from a minimum of three batches. 
 
Jessica Lea Woodman – University of Connecticut, 2014 
 
107 
 
 
Figure 4.2 TEM images of (A) nCaP
CMHA
CDDP and (B) nCaP
D
CDDP, depicting small nCaP 
20-50 nm agglomerated into larger groups of particles. 
 
 
 
 
 
 
 
 
 
 
Jessica Lea Woodman – University of Connecticut, 2014 
 
108 
 
 
Figure 4.3 XRD spectra of (A) nCaP
CMHA 
 suspension (nCaP
CMHA
 wet), lyophilized nCaP
CMHA 
(nCaP
CMHA
 dry) and lyophilized CaP without stabilizer added during precipitation (microCaP 
dry) (B) nCaP
D 
 suspension (nCaP
D
 wet), lyophilized nCaP
D 
(nCaP
D
 dry) and lyophilized CaP 
without stabilizer added during precipitation (microCaP dry). Both plots show hydroxyapatite 
standard (JCPDS, #09-0432) (bars) for comparison. MicroCaP pattern has major peaks 
characteristic of Brushite (peaks denoted with open circles). MicroCaP was precipitated without 
a stabilizer and is crystalline. With a stabilizer present (CMHA or D) the crystallization is halted, 
depicted by broad peaks showing no long range crystal order. 
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Figure 4.4 In vitro release testing using a modified USP Apparatus 4 (dialysis adapter molecular 
weight cut off 100 kDa) of nCaP
CMHA
CDDP and nCaP
D
CDDP. Cumulative CDDP released is 
plotted using the left y-axis, percent CDDP released using right y-axis.  Both formulations 
provide sustained delivery of CDDP for 2 days.  After 2 days nCaP
CMHA
CDDP released 74% of 
bound CDDP available for release and release plateaus. nCaP
D
CDDP released 45% of bound 
CDDP in 2 days.  At study completion, nCaP
CMHA
CDDP released more CDDP faster than 
nCaP
D
CDDP with total percent release at 86% and 74%, respectively. Release in 10 mM PBS 
pH 7.4, 0.1% sodium azide at 37ºC. 
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Figure 4.5 Surface plasmon resonance sensogram depicting binding of CMHA, HA and 
nCaP
CMHA
CDDP with immobilized CD44. All data shown has been corrected for non-specific 
binding to blank channels of blocked NHS-EDC. nCaP
D
CDDP was used as a comparable sized 
control, which does not have specific interactions with CD44. HA has the highest affinity for 
CD44, followed by CMHA then nCaP
CMHA
CDDP. 
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Figure 4.6 Flow cytometry data shows NIH-3T3 cells are CD44
-/low
. These cells will serve as a 
negative control for CD44 targeting, as they have low CD44 expression. (A) Unstained control 
(B) isotype control (C) stained cells with CD44 – Alexa Fluor® 647 against forward scattered 
light (FSC, proportional to cell surface area).  
 
Figure 4.7 Flow cytometry data confirms that LMS cells are CD24
-/low
/CD44
high
. These cells will 
be the experimental group for CD44 targeting, as they have high CD44 expression. (A) 
Unstained control (B) isotype control (C) stained cells with CD44 – Alexa Fluor® 647 and 
CD24 – PE-Cy7. 
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Figure 4.8 Flow cytometry data demonstrates that BT-474 cells are CD24
high
/CD44
low
. These 
cells will serve as the negative control for CD44 targeting, because they lack CD44 expression. 
(A) Unstained control, (B) isotype control, (C) stained cells with CD44 – Alexa Fluor® 647 and 
CD24 – PE-Cy7. BT-474m cells are CD24low/CD44high. These cells will serve as the 
experimental group to investigate CD44 targeting, as they have high CD44 expression.  (D) 
Unstained control, (E) isotype control, (F) stained cells with CD44 – Alexa Fluor® 647 and 
CD24 – PE-Cy7. 
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Figure 4.9 Cellular uptake study using BT-474m cells. Cells were plated and allowed to adhere 
for 24 hours, after which nCaP
CMHA-AF488
 was added at a concentration of 2 mg/mL, in complete 
media. After 18 hours, nCaP
CMHA-AF488 
can clearly be seen within cells as confirmed by z-stack 
images. (A) Cells stained with DAPI, (B) Cells imaged containing nCaP
CMHA-AF488
, (C) Overlay 
of DAPI and AF488 images, showing nCaP
CMHA-AF488
 uptake, and (D) Differential interference 
contrast (DIC) image. 
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Figure 4.10 Mouse fibroblast cells, NIH-3T3, were used to examine the in vitro cytotoxicity of 
CMHA and D. (A) CMHA has no toxicity at a top concentration of 1 mg/mL. (B) D causes 50% 
cell death at a top concentration of 1 mg/mL. (C) Calculated IC50 values of: CDDP, Aq CDDP, 
CDDP released from nCaP
CMHA
CDDP, CDDP released from nCaP
D
CDDP, nCaP
CMHA
CDDP, 
nCaP
D
CDDP, Aq CDDP reacted with CMHA, and Aq CDDP reacted with D.
 
Drug released 
from nCaP
CMHA
CDDP has the same cytotoxicity as free CDDP and Aq CDDP. (One way 
ANOVA with Dunnet post-test, P < 0.05).  Reacting D with Aq CDDP, significantly decreases 
the cytotoxicity of Aq CDDP. Reacting CMHA with Aq CDDP does not inhibit the cytotoxicity 
of Aq CDDP. 
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Figure 4.11 Cytotoxicity testing results in LMS cells. (A) CMHA has no toxicity at a top 
concentration of 1 mg/mL. (B) D causes 75% cell death at a top concentration of 1 mg/mL. (C) 
Calculated IC50 values of: CDDP, Aq CDDP, CDDP released from nCaP
CMHA
CDDP, CDDP 
released from nCaP
D
CDDP, nCaP
CMHA
CDDP, nCaP
D
CDDP, Aq CDDP reacted with CMHA, 
and Aq CDDP reacted with D.
. 
Drug released from nCaP
CMHA
CDDP has the same cytotoxicity as 
free CDDP and Aq CDDP. nCaP
CMHA
CDDP was significantly less cytotoxic than CDDP 
(P<0.05). nCaP
D
CDDP and reacting D with Aq CDDP, are significantly less cytotoxic than 
CDDP (P≤0.001). Reacting CMHA with Aq CDDP does not inhibit the cytotoxicity of Aq 
CDDP. 
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Figure 4.12 Cytotoxicity experiments were conducted using BT-474 (CD44-) and BT-474m 
(CD44+) cells. (A) Against BT-474 cells nCaP
CMHA
CDDP is significantly more cytotoxic than 
CDDP (P≤0.01). nCaPDCDDP and reacting D with Aq CDDP, are significantly less cytotoxic 
than CDDP (P≤0.0001). Reacting CMHA with Aq CDDP does not inhibit the cytotoxicity of Aq 
CDDP.  (B) Against BT-474m cells nCaP
D
CDDP and reacting D with Aq CDDP, are 
significantly less cytotoxic than CDDP (P≤0.0001).  Reacting CMHA with Aq CDDP does not 
inhibit the cytotoxicity of Aq CDDP.  
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Figure 4.13 Flow cytometry data reveals BT 474m cells remain CD24
-/low
/CD44
high
 after 
mycoplasma removal. This ensured that the CD44 high status was maintained after mycoplasma 
removal. (A) Unstained control, (B) isotype controls, (C) stained cells with CD44 – Alexa 
Fluor® 647 and CD24 – PE-Cy7. 
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Figure 4.14 Cytotoxicity evaluations of nanoparticle components using BT-474 and BT-474m 
cells. (A) CMHA is not cytotoxic to either cell type. (B) D is cytotoxic to BT-474m cells at a top 
concentration of 1 mg/mL (C) nCaP
CMHA
 is not cytotoxic, arrow indicates approximate 
nCaP
CMHA
 concentration in IC50 of nCaP
CMHA
CDDP. (D) nCaP
D
 is not cytotoxic, arrow 
indicates approximate nCaP
D
 concentration in IC50 of nCaP
CMHA
CDDP. 
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Figure 4.15 Cytotoxicity evaluation using BT-474 (CD44-) cells in an MTS assay. (A) CDDP, 
(B) Aq CDDP, (C) Aq CDDP reacted with CMHA, (D) Aq CDDP reacted with D, (E) 
nCaP
CMHA
CDDP, and (F) nCaP
D
CDDP. 
 
 
Jessica Lea Woodman – University of Connecticut, 2014 
 
120 
 
 
Figure 4.16 Calculated IC50 values against BT-474 (CD44-) cells, from curves shown in Figure 
4.14.  nCaP
CMHA
CDDP is significantly more cytotoxic than CDDP (P ≤ 0.0001). Reacting D with 
Aq CDDP (AQ CDDP D) is significantly less cytotoxic than CDDP (P ≤ 0.0001). Reacting 
CMHA with Aq CDDP (AQ CDDP CMHA) does not inhibit the cytotoxicity of Aq CDDP.  Aq 
CDDP is significantly more cytotoxic than CDDP (P ≤ 0.0001). 
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Figure 4.17 Cytotoxicity evaluation using BT-474m (CD44+) cells in an MTS assay. (A) 
CDDP, (B) Aq CDDP, (C) Aq CDDP reacted with CMHA, (D) Aq CDDP reacted with D, (E) 
nCaP
CMHA
CDDP, and (F) nCaP
D
CDDP. 
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Figure 4.18 Calculated IC50 values against BT-474m (CD44+) cells, from curves shown in 
Figure 4.16. Reacting D with Aq CDDP (AQ CDDP D) is significantly less cytotoxic than 
CDDP (P ≤ 0.0001). No other groups were significantly different from CDDP. 
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Figure 4.19 (A) Tumor take rate study performed in Athymic nude mice with 5 x 10
5
 BT-474m 
cells injected subcutaneously in right rear flank of animals. Data represents average tumor 
volume vs days following inoculation with standard deviations. (B) Maximum tolerable dose 
study conducted with Athymic nude mice (6-8 weeks old) carrying BT-474m tumors. An 
intratumoral 7 mg/kg dose of nCaP
CMHA
CDDP (4 mice/group) was compared to an untreated 
control (4 mice/group). nCaP
CMHA
CDDP caused minimal weight loss at 7 mg/kg and all animals 
recovered. 
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Figure 4.20 Efficacy study of nCaP
CMHA
CDDP was conducted on J:Nu mice bearing BT-474m 
tumors. Animals were treated once when their tumor volume reached 100 ± 10 mm
3
 and were 
compared to 2.8 mg/kg CDDP administered near the tumor. Tumor volume, grooming and 
weight loss were monitored every other day following treatment.  The graph depicts average 
tumor volume (mm
3
) per group versus days post treatment.  The negative control Saline IT (70 
uL) had no effect on tumor growth. nCaP
CMHA
 (60 uL) had no effect on tumor growth. CDDP at 
2.8 mg/kg administered near the tumor delayed tumor growth. 
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Figure 4.21 Tumor weight at the end of the study or at time of euthanasia for the efficacy study 
shown in Figure 4.19. The study was conducted on J:Nu mice bearing BT-474m tumors. 
Animals were treated once when their tumor volume reached 100 ± 10 mm
3
.  Tumors were 
resected at the end of the study and weighed.  Animals were euthanized if tumor diameter was 
measured > 2 cm or at the completion of the study (Day 30). No significant differences were 
found between groups.  
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Figure 4.22 Survival was plotted for the efficacy study shown in Figure 4.19. The study was 
conducted on J:Nu mice bearing BT-474m tumors. Animals were treated once when their tumor 
volume reached 100 ± 10 mm
3
 and compared to 2.8 mg/kg CDDP administered near tumor (NT). 
Tumor volume, grooming and weight loss were monitored every other day following treatment.  
Survival was defined as a tumor diameter > 2 mm or inability to groom.  A treatment of 7 mg/kg 
nCaP
CMHA
CDDP and  2.8 mg/kg CDDP (NT) were most effective at prolonging survival 
compared to control treatments of Saline or nCaP
CMHA
 (NT).  
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Chapter 5 
Suggested Future Directions and Conclusions 
The goal of these studies was to develop a stabilized, injectable calcium phosphate 
nanoparticle system for the delivery of CDDP that releases biologically active drug and can 
furthermore be targeted to therapy resistant cancer cells.  Using a systematic approach to 
understand the nano-molecular interactions of the stabilizer/drug/nanoparticle system and its 
resulting biological effect, we have revealed pitfalls in stabilizer-drug interactions that were 
previously unknown.  These complex and inherently important interactions are crucial to define 
in order to develop an effective drug delivery system. By studying the interaction of each 
material component with the chemotherapy drug, cancer cells, and tumors, we identified a novel 
stabilizer for nCaP that has biological targeting capacity and importantly does not negatively 
impact the biological efficacy of CDDP.  Sodium polyacrylate and sodium citrate were excellent 
stabilizers for nCaP, but negatively impacted the biological activity of CDDP.  It is essential in 
future work to examine the components of each nanoparticle system as they interact with the 
drug to be delivered as it relates to anticipated biological effect.  This process is not 
commonplace for current nanoparticle research and should be adopted to prevent complications 
moving forward.  
This work highlighted a novel nCaP stabilizer candidate, carboxymethyl hyaluronic acid 
(CMHA).  We showed that nCaP
CMHA
CDDP does bind to CD44, but this binding was much 
lower than that of CMHA alone, which was lower than HA. The chemical modification of HA to 
create CMHA may contribute to the lower binding of CMHA with CD44. Additionally, the 
molecular weight of HA has been shown to significantly impact its binding with CD44, where 
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higher molecular weights have greater binding
170
. The CMHA used in these studies was ~34 
kDa, compared to HA at 60 kDa during SPR experiments. This is a major factor that likely 
contributes to the enhanced binding of HA over CMHA observed.  The incorporation of CMHA 
into nCaP
CMHA
 likely lessens the number of available CD44 binding sites as well as the 
presentation of the molecule to CD44.  With further funding, it would be of interest to study 
varied molecular weights of CMHA, to see if higher molecular weights have increased CD44 
binding similar to HA. A higher molecular weight CMHA will likely change the stabilization of 
nCaP
CMHA
, therefore a balance must be achieved between physical and biological properties of 
the resulting nanoparticle system.   
More research is necessary to understand the interactions of nCaP
CMHA
CDDP and CD44 
expressed on the surface of cancer cells.  The preliminary cell uptake study conducted here was 
able to show uptake of nCaP
CMHA-AF488
 by CD44 positive BT-474m cells, but this is not 
sufficient to prove uptake was mediated by CD44. To do so, thorough cellular uptake studies 
combined with CD44 inhibition or saturation, via pretreatment with HA is necessary
171
.  An 
additional control would be to examine nCaP
CMHA 
uptake by cells that do not express CD44, like 
BT-474 cells.  nCaP
CMHA
CDDP had equivalent cytotoxicity in both CD44
-
 and CD44
+ 
cells 
which is an excellent property for treating tumors in vivo, due to heterogeneity.  This may be due 
to sufficient drug release from nCaP
CMHA
CDDP or possibly cellular uptake is being mediated by 
a mechanism other than CD44 mediated uptake.  
Each nCaP
x
CDDP system that was synthesized was examined in an animal anti-cancer 
efficacy model. Each model utilized a different cell type to create tumors. We examined murine 
head and neck cancer (HNC), human head and neck cancer and human breast cancer, in order to 
demonstrate a broad range of activity.  As a hypothesized negative control, we included a group 
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in each study that received an intratumoral injection of CDDP alone at the maximum tolerated 
volume.  This was compared to an experimental group of an intratumoral dose of nCaP
x
CDDP at 
the same volume, which delivered a significantly higher dose of CDDP, due to the high drug 
loading capacity of nCaP. In four out of five animal studies, local delivery of CDDP without 
nanoparticles was the most effective at delaying tumor growth.  In Chapter 3, we utilized human 
HNC (FaDu) cells in a subcutaneous tumor model and found that a 1.4 mg/kg intratumoral dose 
of CDDP was sufficient to cause significant tumor growth delay.  In that study, all animals in the 
CDDP IT treatment group survived the full length of the study, 30 days.  This finding is 
completely novel and to our knowledge nothing comparable has been published.  The efficacy of 
this treatment is likely due to the ability of CDDP to diffuse freely into the tumor with local 
administration.  Each nCaP
x
CDDP IT or NT treatment did not evenly distribute throughout the 
tumor as hypothesized.  This was evident in the work performed in Chapter 4 with 
nCaP
CMHA
CDDP.  Tumors were resected at the time of euthanasia and those animals treated near 
tumor with nCaP
CMHA
CDDP had obvious deposits of nanoparticles.  Interestingly, tumors were 
smaller when two deposits of nCaP
CMHA
CDDP were present versus larger tumors when only one 
deposit of nCaP
CMHA
CDDP was found.  When nCaP
CMHA
CDDP was administered the goal was 
to deposit the nanoparticles in two locations opposite one another, but for some tumors this was 
not achieved.  We believe the lack of distribution of nCaP
CMHA
CDDP throughout the tumor 
contributed to the lack of efficacy observed because drug exposure was limited to one side of the 
tumor.  Moving forward nCaP
CMHA
CDDP could be given using intravenous (IV) administration 
to aid in distribution of nCaP
CMHA
CDDP throughout the tumor.  IV administration will allow 
nCaP
CMHA
CDDP to passively target the tumor via the enhanced permeability and retention (EPR) 
effect
7,172–174
 in addition to active targeting via CD44 expression in cancer cells.  Once 
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nCaP
CMHA
CDDP reaches the tumor, CD44 mediated uptake
175
 and an acidic tumor 
microenvironment will enhance CDDP release locally.  
Choice of animal model is essential to obtaining statistically significant, meaningful 
results.  Within this dissertation we studied mouse HNC via SCCVII cells in CH3/HeJ mice, 
human HNC via FaDu cells in Nu/J mice and human TNBC via BT-474m cells in J:Nu mice.  
SCCVII cells are very aggressive, which is well published
63,128,176
.  This model was chosen 
because of their aggressive phenotype, with the goal of overcoming the fast tumor growth with 
local delivery of CDDP via nCaP
D
CDDP.  We found that only local delivery of CDDP had a 
significant effect at delaying tumor growth and this was only found when all animals were 
treated when their tumor volume reached strictly within ±10% of one another, specifically 160 
mm
3
 for the second efficacy study (Figure 2.19).  Due to the aggressive nature of these tumors 
only 20% of animals remained in the most effective treatment group, CDDP IT, at the 20 day 
completion of the study. All other animals had to be euthanized due to a tumor diameter > 2 cm, 
weight loss, or tumor necrosis, prior to day 20 following treatment.  This model is too aggressive 
and consequently we moved to the use of a human HNC model, which employed FaDu cells.  
FaDu cells proved to be less aggressive, where animals treated with control treatments of saline 
or nCaP
CIT
 alone were able to survive for 16 to 27 days and all of the animals in the CDDP IT 
treatment group survived 30 days. This model proved to develop tumors that when left untreated, 
all grew within a close tumor volume range of one another, which limited variability within 
treatment groups.  Additionally, necrosis and rapid tumor growth (diameter > 2 cm 10 days 
following treatment) was not an issue.  In Chapter 4 of this dissertation, we aimed to target 
human, CD44 expressing, therapy resistant TNBC.  BT-474m cells proved to be an excellent 
model for this in vitro but when these cells were inoculated in J:Nu mice their growth was highly 
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variable.  This may be due to an insufficient number of cells injected, loss of aggressive 
phenotype in vivo or an immune response in the J:Nu mice.  We chose to use this cell type 
because they uniquely represent a sub-set of transformed, triple negative breast cancer (TNBC) 
cells which are CD44
+
/CD24
-
.  This type of cancer cell has not previously been examined for in 
vivo tumor take rate or anti-cancer efficacy using CDDP, but has excellent clinical relevance 
towards more effective treatment of TNBC.  It is likely that moving forward with this cell line 
will require inoculating mice with a higher concentration of cells, where we injected 5 x 10
5 
and 
something more comparable to what was used for FaDu tumors would be more appropriate, 2 x 
10
6
 cells.  This can be evaluated using an additional tumor take rate study.  It is essential to 
determine an appropriate animal model that will result in tumors that will grow beyond 
inoculation volume, but are not too aggressive causing necrosis and tumor diameters above limits 
set by Institutional Animal Care.  
Overall, nCaP
CMHA
CDDP shows great promise for the treatment of TNBC. CD44 
expression is also common in HNC
37,177–180
, therefore revisiting the HNC model in vitro and in 
vivo with the nCaP
CMHA
CDDP formulation is of interest.  A thorough maximum tolerable dose 
study with a wider range of doses of nCaP
CMHA
CDDP should be performed prior to a repeat 
efficacy study.  It is likely that a higher dose of nCaP
CMHA
CDDP will be safe, as no animals lost 
more than 5% of their weight at time of treatment due to the 7 mg/kg dose used in Chapter 4. 
The cytotoxicity studies were very promising and thus we anticipated significant tumor growth 
delay in vivo.  With thorough characterization and optimization nCaP
CMHA
CDDP has excellent 
potential for localized treatment of CD44+ cancers, like TNBC and HNC.   
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